<!DOCTYPE html><html lang="en-GB"><head><meta charSet="utf-8"/><meta http-equiv="x-ua-compatible" content="ie=edge"/><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/><style data-href="/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css" id="gatsby-global-css">.page-header{margin:0 0 3rem}.page-header__pre-heading{font-size:1.125rem;line-height:1.5rem;display:block;margin:0}.page-header__heading{font-size:2.75rem;line-height:3.5rem;margin:0 0 .5rem}.page-header__lead{font-size:1.25rem;line-height:1.75rem;margin:0 0 .5rem}.page-header__cta{font-size:1rem;line-height:1.5rem;display:block;margin:0}@media print{.page-header__cta{display:none!important}}.breadcrumbs{font-size:1rem;line-height:1.5rem;list-style:none;margin:.5em 0 2em;max-width:100%;padding:0}@media print{.breadcrumbs{display:none!important}}.breadcrumbs__crumb{display:inline-block}.breadcrumbs__crumb:before{content:">";font-size:80%;margin:0 .25em}.breadcrumbs__crumb:first-child:before{display:none}.breadcrumbs a{color:#222;text-decoration:underline}.breadcrumbs a:hover{text-decoration:none}.breadcrumbs a:focus{color:#005ea5}.breadcrumbs a:active{color:#222}.OldIEMessage-module--container--2Z9pT{max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);margin:auto auto 1rem}.OldIEMessage-module--alert--3CB3M{background:#ffdfa4;border:1px solid #966f2f;margin:1rem auto 0;max-width:73.125rem;padding:1rem}.OldIEMessage-module--alert--3CB3M a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.OldIEMessage-module--alert--3CB3M a:visited{color:#4c2c92}.OldIEMessage-module--alert--3CB3M a:hover{color:#2e8aca}.OldIEMessage-module--alert--3CB3M a:focus{outline:.25rem solid #0092a6;color:#005ea5}.OldIEMessage-module--alert--3CB3M a:active{color:#222}.OldIEMessage-module--alert--3CB3M h2{margin-top:0}.OldIEMessage-module--alert--3CB3M h2,.OldIEMessage-module--alert--3CB3M p{max-width:600px}.OldIEMessage-module--lastP---CQws{margin-bottom:0}.CoronaMessage-module--wrapper--zRiaV{background:#ffeb3b;padding:.5rem 0}.CoronaMessage-module--wrapper--zRiaV p{margin-top:0}.CoronaMessage-module--wrapper--zRiaV a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.CoronaMessage-module--wrapper--zRiaV a:visited{color:#4c2c92}.CoronaMessage-module--wrapper--zRiaV a:hover{color:#2e8aca}.CoronaMessage-module--wrapper--zRiaV a:focus{outline:.25rem solid #0092a6;color:#005ea5}.CoronaMessage-module--wrapper--zRiaV a:active{color:#222}@media print{.CoronaMessage-module--wrapper--zRiaV{display:none}}.CoronaMessage-module--container--36Biz{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.CoronaMessage-module--container--36Biz>:last-child{margin-bottom:0}.SubNav-module--wrapper--yAXWY{background:#fff;color:#000;display:block}.SubNav-module--list--1K9bK{margin:0;padding:0}.SubNav-module--list--1K9bK li{list-style:none;margin:0}.SubNav-module--link--39i23{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222;display:block;font-weight:400;padding:.5rem 1rem .5rem 2rem;text-decoration:none}.SubNav-module--link--39i23:focus{color:#222;outline:.25rem solid #0092a6;outline-offset:-.5rem}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#222}.SubNav-module--link--39i23:hover{background:#d6d6d6;color:#222;text-decoration:underline}.SubNav-module--imageLink--3xwIS{display:none}@media(min-width:56.25em){.SubNav-module--wrapper--yAXWY{border-bottom:.125rem solid #004650;bottom:0;height:3rem;left:0;position:absolute;width:100%}.SubNav-module--imageLink--3xwIS{display:inline-block}.SubNav-module--list--1K9bK{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);height:100%}.SubNav-module--list--1K9bK li{display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23{border:0;display:block;height:100%;padding:0 1rem}.SubNav-module--link--39i23[aria-current=page],.SubNav-module--link--39i23[aria-current=true]{background:transparent}.SubNav-module--link--39i23[aria-current=page]:after,.SubNav-module--link--39i23[aria-current=true]:after{display:none}.SubNav-module--link--39i23:before{content:"";display:inline-block;height:100%;vertical-align:middle}.SubNav-module--link--39i23:active,.SubNav-module--link--39i23:hover,.SubNav-module--link--39i23:visited{border:0}}.SubNav-module--image--uq-a2{height:100%}.Nav-module--link--3JzDA .Nav-module--tooltip--1Uj-W{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Nav-module--link--3JzDA:focus-visible .Nav-module--tooltip--1Uj-W{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Nav-module--visuallyHidden--ORHqX{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Nav-module--wrapper--2_xng{display:none;position:relative}@media print{.Nav-module--wrapper--2_xng{display:none!important}}@media(min-width:56.25em){.Nav-module--wrapper--2_xng{display:block}}.Nav-module--wrapperExpanded--3RxQB{display:block}.Nav-module--nav--2aQpa abbr[title]{border-bottom:0;cursor:help;text-decoration:none}.Nav-module--myAccount--3lsif{border-top:1px solid #fff}@media(min-width:56.25em){.Nav-module--myAccount--3lsif{display:none}}.Nav-module--myAccountHeading--1A5_B{border:.25rem solid #004650;font-size:100%;margin:0;padding:.5rem 1rem}.Nav-module--menuWrapper--2fp8S{background:#004650;color:#fff;padding:.25rem 0}.Nav-module--menuList--264L-{list-style:none;margin:auto;padding:0}.Nav-module--menuList--264L->li{margin:0}a.Nav-module--link--3JzDA{border-color:#004650;border-style:solid;border-width:0 .25rem;color:#fff;display:block;font-weight:400;padding:.5rem 1rem;text-decoration:none}a.Nav-module--link--3JzDA span{text-decoration:inherit}a.Nav-module--link--3JzDA:focus{color:#fff;outline:.25rem solid #fff;outline-offset:-.5rem;z-index:1}a.Nav-module--link--3JzDA:visited{color:#fff}a.Nav-module--link--3JzDA:active{background:#acadad;color:#222}a.Nav-module--link--3JzDA:hover{background:#d6d6d6;color:#222;text-decoration:underline}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{background:#fff;color:#222;font-weight:700}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-color:#0092a6;outline-offset:-.25rem}@media(min-width:56.25em){.Nav-module--wrapperWithSubLinks--3PUfX{padding-bottom:3rem}.Nav-module--menuList--264L-{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);display:-webkit-flex;display:flex;-webkit-flex-direction:row;flex-direction:row;-webkit-flex-wrap:nowrap;flex-wrap:nowrap;-webkit-justify-content:space-between;justify-content:space-between}.Nav-module--menuList--264L->li{-webkit-flex-grow:1;flex-grow:1}a.Nav-module--link--3JzDA{border-left-width:0;border-right-width:0;display:-webkit-flex;display:flex;-webkit-flex-direction:column;flex-direction:column;height:100%;-webkit-justify-content:center;justify-content:center;line-height:1.25;margin:0;padding:.5rem;position:relative;text-align:center}a.Nav-module--link--3JzDA:focus{outline-offset:-.25rem}a.Nav-module--link--3JzDA span{display:inline-block;vertical-align:middle;white-space:normal}a.Nav-module--link--3JzDA[aria-current=page],a.Nav-module--link--3JzDA[aria-current=true]{margin:0 .25rem}a.Nav-module--link--3JzDA[aria-current=page]:focus,a.Nav-module--link--3JzDA[aria-current=true]:focus{outline-offset:-.5rem}a.Nav-module--link--3JzDA[aria-current=page]:after,a.Nav-module--link--3JzDA[aria-current=true]:after{background:#fff;content:"";display:block;height:.25rem;left:0;position:absolute;top:100%;width:100%}a.Nav-module--link--3JzDA[aria-current=page]:hover:after,a.Nav-module--link--3JzDA[aria-current=true]:hover:after{background:#d6d6d6}}@media(min-width:56.25em)and (min-width:75em){a.Nav-module--link--3JzDA{padding:1rem}}.Autocomplete-module--ac--2PqiF .autocomplete__wrapper{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input{-webkit-appearance:none;border:1px solid #222;border-radius:0;box-sizing:border-box;margin-bottom:0;width:100%}.Autocomplete-module--ac--2PqiF .autocomplete__input{background-color:#e9e9e9!important;height:2.5rem!important;margin:0!important;max-width:100%!important;position:relative;z-index:101}.Autocomplete-module--ac--2PqiF .autocomplete__input:focus{outline:3px solid #0092a6;outline-offset:-3px;z-index:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-webkit-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-moz-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input:-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::-ms-input-placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__input::placeholder{color:#666!important;font-size:100%;font-weight:400;opacity:1}.Autocomplete-module--ac--2PqiF .autocomplete__hint{color:#bfc1c3;position:absolute}.Autocomplete-module--ac--2PqiF .autocomplete__input--default{padding:.5rem}.Autocomplete-module--ac--2PqiF .autocomplete__input--focused{outline:3px solid #0092a6;outline-offset:-3px}.Autocomplete-module--ac--2PqiF .autocomplete__input--show-all-values{padding:4px 34px 4px 4px;cursor:pointer}.Autocomplete-module--ac--2PqiF .autocomplete__dropdown-arrow-down{z-index:-1;display:inline-block;position:absolute;right:8px;width:24px;height:24px;top:10px}.Autocomplete-module--ac--2PqiF .autocomplete__menu{background-color:#fff;border:1px solid #d6d6d6;border-top:0;color:#34384b;margin:0;max-width:100%;padding:0;text-align:left;width:-webkit-calc(100vw - 2rem);width:calc(100vw - 2rem)}@media(min-width:37.5em){.Autocomplete-module--ac--2PqiF .autocomplete__menu{width:100%}}.Autocomplete-module--ac--2PqiF .autocomplete__menu--visible{display:block}.Autocomplete-module--ac--2PqiF .autocomplete__menu--hidden{display:none}.Autocomplete-module--ac--2PqiF .autocomplete__menu--overlay{box-shadow:0 .25rem 1rem .25rem rgba(0,0,0,.1);left:0;position:absolute;top:100%;z-index:100}.Autocomplete-module--ac--2PqiF .autocomplete__menu--inline{position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option{border-left-width:0;border-bottom:1px solid #d6d6d6;border-right-width:0;border-top-width:1px;color:#005ea5;cursor:pointer;display:block;margin:0;position:relative}.Autocomplete-module--ac--2PqiF .autocomplete__option a{color:inherit;display:block;font-weight:400;padding:.5rem;text-decoration:none}.Autocomplete-module--ac--2PqiF .autocomplete__option mark{background:0;color:inherit;font-weight:700;padding:0}.Autocomplete-module--ac--2PqiF .autocomplete__option>*{pointer-events:none}.Autocomplete-module--ac--2PqiF .autocomplete__option:first-of-type{border-top-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option:last-of-type{border-bottom-width:0}.Autocomplete-module--ac--2PqiF .autocomplete__option--odd{background-color:#fafafa}.Autocomplete-module--ac--2PqiF .autocomplete__option--focused,.Autocomplete-module--ac--2PqiF .autocomplete__option:hover{background-color:#e9e9e9;color:#005ea5;outline:none;text-decoration:underline}.Autocomplete-module--ac--2PqiF .autocomplete__option--no-results{background-color:#fafafa;color:#646b6f;cursor:not-allowed}.Autocomplete-module--ac--2PqiF .autocomplete__hint,.Autocomplete-module--ac--2PqiF .autocomplete__input,.Autocomplete-module--ac--2PqiF .autocomplete__option{font-size:16px;line-height:1.25}.Search-module--search--2wNll{margin:0;padding-right:2.5rem;position:relative}.Search-module--label--1rrog{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute!important;width:1px}.Search-module--button--2FbnI{background:#393939;border:0;color:#fff;cursor:pointer;height:2.5rem;min-width:2.5rem;padding:0 .5rem;position:absolute;right:0;text-align:center;top:0;z-index:101}.Search-module--button--2FbnI:focus{outline:.25rem solid #0092a6}.Search-module--button--2FbnI .Search-module--icon--2JB42{font-size:150%;vertical-align:middle}.Account-module--account--1BtRh{position:relative}.Account-module--button--zZii1{background:#fff;border:1px solid #222;color:#222;cursor:pointer;display:inline-block;font-family:inherit;font-size:inherit;font-weight:400;height:2.5rem;line-height:2.5rem;padding:0 .5rem;text-decoration:none;vertical-align:middle;white-space:nowrap}.Account-module--button--zZii1:focus{outline:.25rem solid #0092a6}.Account-module--button--zZii1:visited{color:#222}.Account-module--button--zZii1:hover{border:1px solid #222}.Account-module--myAccount--3jTaq:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Account-module--myAccount--3jTaq[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Account-module--menu--3C46i{background:#fff;border:1px solid #393939;list-style:none;margin:.625rem 0 0;padding:0;position:absolute;right:0;top:100%;z-index:2}.Account-module--menu--3C46i:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i[aria-hidden=true]{display:none}.Account-module--menu--3C46i:before{border-bottom:.5rem solid #393939;border-left:.25rem solid transparent;border-right:.25rem solid transparent}.Account-module--menu--3C46i:after,.Account-module--menu--3C46i:before{bottom:100%;content:"";display:block;height:0;position:absolute;right:1rem;width:0}.Account-module--menu--3C46i:after{border-bottom:.4rem solid #fff;border-left:.2rem solid transparent;border-right:.2rem solid transparent;margin-right:1px}.Account-module--menu--3C46i li{border-top:1px solid #d6d6d6;list-style:none;margin:0}.Account-module--menu--3C46i a{color:#005ea5;display:block;padding:.5rem 1rem;text-decoration:none;white-space:nowrap}.Account-module--menu--3C46i a:focus{outline:.25rem solid #0092a6}.Account-module--menu--3C46i a:hover{background:#e9e9e9;text-decoration:underline}.Header-module--header--3os44{background:#fff;border-bottom:.125rem solid #004650;box-sizing:border-box;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif}.Header-module--header--3os44 *,.Header-module--header--3os44 :after,.Header-module--header--3os44 :before{box-sizing:inherit;font-family:inherit}@media print{.Header-module--header--3os44{border-bottom:none}}.Header-module--container--1mfIr{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0 0}.Header-module--container--1mfIr:after{clear:both;content:"";display:table}.Header-module--home--1TCPb{color:#000;display:inline-block;float:left;height:1.875rem;margin-bottom:1rem}@media print{.Header-module--home--1TCPb:after{content:none!important}}.Header-module--home--1TCPb:focus{outline:.25rem solid #0092a6}.Header-module--home--1TCPb:visited{color:#000}.Header-module--home--1TCPb .Header-module--icon--4LSt5{height:100%;width:auto}.Header-module--wrapper--2e13D{display:-webkit-flex;display:flex;-webkit-flex-grow:1;flex-grow:1;float:right;-webkit-justify-content:space-between;justify-content:space-between;margin-bottom:1rem;width:50%}@media print{.Header-module--wrapper--2e13D{display:none!important}}.Header-module--wrapper--2e13D:after{clear:both;content:"";display:table}.Header-module--search--2nfnz{-webkit-flex-grow:1;flex-grow:1;float:left;margin-right:1rem;min-width:66.6666666667%}.Header-module--mobileMenuBtn--1LgyL{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:1px solid #222;float:right;font-family:inherit;font-size:110%;height:2.5rem;min-width:4.6875rem;white-space:nowrap}.Header-module--mobileMenuBtn--1LgyL:after{border-left:.25rem solid transparent;border-right:.25rem solid transparent;border-top:.5rem solid #393939;content:"";display:inline-block;height:0;margin-left:.5rem;vertical-align:middle;width:0}.Header-module--mobileMenuBtn--1LgyL[aria-expanded=true]:after{border-bottom:.5rem solid #222;border-top:0}.Header-module--account--y72Q4{display:none}@media(max-width:56.24em){.Header-module--home--1TCPb{float:none}.Header-module--wrapper--2e13D{float:none;width:auto}}@media(min-width:56.25em){.Header-module--header--3os44{border-bottom:.25rem solid #fff}.Header-module--container--1mfIr{display:-webkit-flex;display:flex;-webkit-justify-content:space-between;justify-content:space-between}.Header-module--home--1TCPb{height:2.5rem;margin-right:2rem}.Header-module--wrapper--2e13D{-webkit-justify-content:flex-end;justify-content:flex-end}.Header-module--search--2nfnz{margin-right:2rem}.Header-module--mobileMenuBtn--1LgyL{display:none}.Header-module--account--y72Q4{display:block}}.SkipLinks-module--list--1WwLa{list-style:none;margin:0;padding:0}@media print{.SkipLinks-module--list--1WwLa{display:none!important}}.SkipLinks-module--list--1WwLa li{list-style:none;margin:0}.SkipLinks-module--link--hkZw8{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.SkipLinks-module--link--hkZw8:focus{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;left:.25rem;outline:3px solid #0092a6;overflow:visible;padding:.5rem 1rem;position:absolute;top:.25rem;white-space:nowrap;width:auto;z-index:1}.Social-module--wrapper--2nKsd{clear:left}.Social-module--list--E5R5J{list-style:none;margin:0;max-width:100%;padding:0}.Social-module--list--E5R5J li{margin:0 0 .25rem}.Social-module--list--E5R5J svg{margin:-.125rem .25rem 0 0;vertical-align:middle}@media(min-width:37.5em){.Social-module--list--E5R5J li{float:left;margin:0 1rem 0 0}}@media(min-width:56.25em){.Social-module--wrapper--2nKsd{clear:none}.Social-module--wrapper--2nKsd li{float:none;margin:0 0 .25rem}}.Legal-module--wrapper--3AYMO{font-size:.875rem;line-height:1.25rem;background:#393939;padding:1rem 0}.Legal-module--wrapper--3AYMO a{text-decoration:underline}.Legal-module--container--3TTBh{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.Legal-module--menu--1e1Iy{margin:0 0 1rem}@media print{.Legal-module--menu--1e1Iy{display:none!important}}.Legal-module--menu--1e1Iy ul{list-style:none;margin:0;max-width:100%;padding:0}.Legal-module--menu--1e1Iy li{margin:0}.Legal-module--menu--1e1Iy a{display:block}.Legal-module--copyright--34nsI{font-size:.875rem;line-height:1.25rem;margin:0}@media print{.Legal-module--copyright--34nsI{float:none!important;max-width:100%}}@media(min-width:37.5em){.Legal-module--menu--1e1Iy li{display:inline-block;margin-right:1rem}}@media(min-width:75em){.Legal-module--wrapper--3AYMO:after,.Legal-module--wrapper--3AYMO:before{content:" ";display:table}.Legal-module--wrapper--3AYMO:after{clear:both}.Legal-module--menu--1e1Iy{float:left;margin:0}.Legal-module--copyright--34nsI{float:right}}.Services-module--link--2y_1q .Services-module--tooltip--pg3nW{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Services-module--link--2y_1q:focus-visible .Services-module--tooltip--pg3nW{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Services-module--visuallyHidden--t9mfm{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Services-module--wrapper--2qOoE{margin:0 0 2rem}.Services-module--list--3SZQu{list-style:none;margin:0;padding:0}.Services-module--list--3SZQu li{margin:0 0 .25rem}@media(min-width:37.5em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;width:33.3333333333%}}@media(min-width:56.25em){.Services-module--wrapper--2qOoE{border-right:2px solid #393939;float:left;margin:0;width:25%}}.Pages-module--wrapper--30REl{margin:0 0 2rem}.Pages-module--list--vvSk4{list-style:none;margin:0;padding:0}.Pages-module--list--vvSk4 li{margin:0 0 .25rem}@media(min-width:25em){.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}@media(min-width:37.5em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 0 0 2rem;width:66.6666666667%}}@media(min-width:56.25em){.Pages-module--wrapper--30REl{float:left;margin:0;padding:0 2rem;width:50%}.Pages-module--list--vvSk4{-webkit-column-count:2;-moz-column-count:2;column-count:2;-webkit-column-gap:1rem;-moz-column-gap:1rem;column-gap:1rem}}.Footer-module--link--CGIYk .Footer-module--tooltip--1zoJv{clip:rect(1px 1px 1px 1px);clip:rect(1px,1px,1px,1px);height:1px;overflow:hidden;position:absolute;width:1px}.Footer-module--link--CGIYk:focus-visible .Footer-module--tooltip--1zoJv{background:#fff;clip:auto;color:#005ea5;display:block;height:auto;outline:1px solid #0092a6;overflow:visible;padding:0 .25rem;position:absolute;width:auto;z-index:1}.Footer-module--visuallyHidden--3CCnP{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.Footer-module--footer--2QrGZ{background:#222;box-sizing:border-box;color:#fff;contain-intrinsic-size:350px;content-visibility:auto;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;margin:2rem 0 0}.Footer-module--footer--2QrGZ a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.Footer-module--footer--2QrGZ a:visited{color:#fff}.Footer-module--footer--2QrGZ a:hover{color:#d6d6d6}.Footer-module--footer--2QrGZ a:focus{outline:.25rem solid #fff;color:#fff}.Footer-module--footer--2QrGZ a:active{color:#d6d6d6}.Footer-module--footer--2QrGZ *,.Footer-module--footer--2QrGZ :after,.Footer-module--footer--2QrGZ :before{box-sizing:inherit}.Footer-module--footer--2QrGZ a{font-weight:400}.Footer-module--container--1iuoB{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem);padding:1rem 0}.Footer-module--container--1iuoB:after,.Footer-module--container--1iuoB:before{content:" ";display:table}.Footer-module--container--1iuoB:after{clear:both}@media print{.Footer-module--container--1iuoB{display:none!important}}.Footer-module--logo--3DGKv{display:block;height:0;margin:0 0 2rem;padding:0 0 29.0496453901px;position:relative;width:80px}.Footer-module--logo--3DGKv svg{display:block;height:100%!important;left:0;position:absolute;top:0;width:100%!important}@media(min-width:56.25em){.Footer-module--logo--3DGKv{margin-bottom:1rem}}.BackToTop-module--wrapper--2Z0EU{margin-top:3rem}@media print{.BackToTop-module--wrapper--2Z0EU{display:none}}.BackToTop-module--nav--1DPZ6{background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}.BackToTop-module--anchor--1Nia6{display:block;line-height:1rem;padding:1rem 0}.BackToTop-module--anchor--1Nia6:visited{color:#005ea5}.BackToTop-module--anchor--1Nia6 svg{-webkit-transition:all .25s ease;transition:all .25s ease}.BackToTop-module--anchor--1Nia6:hover{background:#f4f4f4}.BackToTop-module--anchor--1Nia6:hover svg{-webkit-transform:translateY(-.125rem);transform:translateY(-.125rem)}@supports((position:-webkit-sticky) or (position:sticky)){.BackToTop-module--wrapper--2Z0EU{bottom:0;left:0;margin:0;pointer-events:none;position:absolute;right:0;top:min(100vh,-webkit-calc(100% - 3rem));top:min(100vh,calc(100% - 3rem));width:100%;z-index:99}.BackToTop-module--nav--1DPZ6{position:-webkit-sticky;position:sticky;pointer-events:all;top:-webkit-calc(100vh - 3rem);top:calc(100vh - 3rem);background:#e9e9e9;border-top:1px solid #adadad;width:100%;z-index:1}}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-regular.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-regular.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:italic;font-weight:400;src:local("Lato"),url(../../../../fonts/lato-v17-latin-italic.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-italic.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:700;src:local("Lato"),url(../../../../fonts/lato-v17-latin-700.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-700.woff) format("woff")}@font-face{font-display:optional;font-family:Lato;font-style:normal;font-weight:900;src:local("Lato"),url(../../../../fonts/lato-v17-latin-900.woff2) format("woff2"),url(../../../../fonts/lato-v17-latin-900.woff) format("woff")}/*! normalize.css v8.0.1 | MIT License | github.com/necolas/normalize.css */html{line-height:1.15;-webkit-text-size-adjust:100%}body{margin:0}main{display:block}h1{font-size:2em;margin:.67em 0}hr{box-sizing:content-box;height:0;overflow:visible}pre{font-family:monospace,monospace;font-size:1em}a{background-color:transparent}abbr[title]{border-bottom:none;text-decoration:underline;-webkit-text-decoration:underline dotted;text-decoration:underline dotted}b,strong{font-weight:bolder}code,kbd,samp{font-family:monospace,monospace;font-size:1em}small{font-size:80%}sub,sup{font-size:75%;line-height:0;position:relative;vertical-align:baseline}sub{bottom:-.25em}sup{top:-.5em}img{border-style:none}button,input,optgroup,select,textarea{font-family:inherit;font-size:100%;line-height:1.15;margin:0}button,input{overflow:visible}button,select{text-transform:none}[type=button],[type=reset],[type=submit],button{-webkit-appearance:button}[type=button]::-moz-focus-inner,[type=reset]::-moz-focus-inner,[type=submit]::-moz-focus-inner,button::-moz-focus-inner{border-style:none;padding:0}[type=button]:-moz-focusring,[type=reset]:-moz-focusring,[type=submit]:-moz-focusring,button:-moz-focusring{outline:1px dotted ButtonText}fieldset{padding:.35em .75em .625em}legend{box-sizing:border-box;color:inherit;display:table;max-width:100%;padding:0;white-space:normal}progress{vertical-align:baseline}textarea{overflow:auto}[type=checkbox],[type=radio]{box-sizing:border-box;padding:0}[type=number]::-webkit-inner-spin-button,[type=number]::-webkit-outer-spin-button{height:auto}[type=search]{-webkit-appearance:textfield;outline-offset:-2px}[type=search]::-webkit-search-decoration{-webkit-appearance:none}::-webkit-file-upload-button{-webkit-appearance:button;font:inherit}details{display:block}summary{display:list-item}[hidden],template{display:none}.show-print{display:none!important}@media print{.show-print{display:block!important}}@media print{.hide-print{display:none!important}}@media print{.remove-appended-print-link:after{content:none!important}}@media print{*{background:transparent!important;box-shadow:none!important;color:#000!important;text-shadow:none!important}a,a:visited{text-decoration:underline}}@media print{h1 a:after,h2 a:after,h3 a:after,h4 a:after,h5 a:after,h6 a:after{content:none!important}}@media print{a[href]:after{content:" (" attr(href) ")"}}@media print{abbr[title]:after{content:" (" attr(title) ")"}}@media print{.ir a:after,a[href^="#"]:after,a[href^="javascript:"]:after{content:""}}@media print{blockquote,pre{border:1px solid #999;page-break-inside:avoid}}@media print{thead{display:table-header-group}}@media print{img,tr{page-break-inside:avoid}}@media print{img{max-width:100%!important}}@media print{img:not([alt]),img[alt=""]{display:none!important}}@media print{@page{margin:.5cm}}@media print{h2,h3,p{orphans:3;widows:3}}@media print{h2,h3{page-break-after:avoid}}.clearfix:after,.clearfix:before{content:" ";display:table}.clearfix:after{clear:both}.container{margin:auto;max-width:73.125rem;width:96%;width:-webkit-calc(100% - 2rem);width:calc(100% - 2rem)}.container--full{max-width:100%;padding:0 2%;width:auto}html{box-sizing:border-box;font-size:.9375rem;overflow-x:hidden}html *,html :after,html :before{box-sizing:inherit}@media(min-width:56.25em){html{font-size:1.03125rem;font-size:-webkit-calc(.375rem + 1vw);font-size:calc(.375rem + 1vw)}}@media(min-width:75em){html{font-size:1.125rem}}body{background:#f4f4f4;color:#222;font-family:Lato,Helvetica Neue,Helvetica,Arial,sans-serif;font-style:normal;line-height:1.5rem;overflow-x:hidden;text-rendering:optimizelegibility}img{max-width:100%}hr{background:0;border:0;border-top:.0625em solid #adadad;margin:2em 0;padding:0}.p,p{font-size:1rem;line-height:1.5rem;font-feature-settings:"kern","onum","liga"}.lead,.p,p{margin-bottom:1rem;margin-top:1rem;font-weight:400;max-width:66ch}.lead{font-size:1.25rem;line-height:1.75rem}code{background:#e9e9e9;border:1px solid #adadad;border-radius:.125em;color:#222;display:inline-block;font-family:Monaco,Menlo,Consolas,Courier New,monospace;margin:0 0 .125em;padding:0 .25em}pre code{background:transparent;border:0;margin:0}.mark,mark{background-color:#fff999;padding:0 .25em}.small,small{font-size:85%}.h6,h6{font-size:1rem}.h5,.h6,h5,h6{line-height:1.5rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h5,h5{font-size:1.125rem}.h4,h4{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:1rem;clear:both;font-weight:700;max-width:66ch}.h3,h3{font-size:1.75rem;line-height:2rem}.h2,.h3,h2,h3{margin-bottom:1rem;margin-top:2rem;clear:both;font-weight:700;max-width:66ch}.h2,h2{font-size:2.25rem;line-height:2.5rem}.h1,.h2+.h3,.h2+h3,h1,h2+.h3,h2+h3{margin-top:0}.h1,h1{font-size:2.75rem;line-height:3.5rem;margin-bottom:1rem;clear:both;font-weight:900;max-width:66ch}.h1+.h2,.h1+h2,h1+.h2,h1+h2{margin-top:0}a{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}a:visited{color:#4c2c92}a:hover{color:#2e8aca}a:focus{outline:.25rem solid #0092a6;color:#005ea5}a:active{color:#222}.link--inverse{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.link--inverse:visited{color:#fff}.link--inverse:hover{color:#d6d6d6}.link--inverse:focus{outline:.25rem solid #fff;color:#fff}.link--inverse:active{color:#d6d6d6}.inverse-links a{color:#fff;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto}.inverse-links a:visited{color:#fff}.inverse-links a:hover{color:#d6d6d6}.inverse-links a:focus{outline:.25rem solid #fff;color:#fff}.inverse-links a:active{color:#d6d6d6}.list,ol,ul{font-feature-settings:"kern","onum","liga";margin-left:1rem;max-width:66ch;padding:0}.list--unstyled{list-style:none;margin-left:0;max-width:none;padding:0}.list--loose .list__item,.list--loose li{margin-bottom:.25rem}.list--piped{list-style:none;margin-left:0;padding:0}.list--piped .list__item,.list--piped li{display:inline-block;margin-right:-.25rem}.list--piped .list__item a,.list--piped li a{padding:.5rem}.list--piped .list__item:after,.list--piped li:after{border-left:1px solid #004650;content:"\200B";display:inline-block;margin:0 .5em;overflow:hidden;text-indent:-99px;vertical-align:middle;width:0}.list--piped .list__item:first-child a,.list--piped li:first-child a{padding-left:0}.list--piped .list__item:last-child:after,.list--piped li:last-child:after{display:none}.quote{font-size:1.25rem;line-height:1.75rem;border-left:.25em solid #004650;font-weight:400;margin:2rem 0;padding:0 0 0 4rem;position:relative}.quote:before{color:#004650;content:"\201C";display:block;font-family:Arial,sans-serif;font-size:5rem;font-weight:700;left:0;line-height:.8;position:absolute;text-align:center;top:0;width:4rem}@media print{.quote:before{color:#000}}.quote p{font-size:inherit}.quote cite,.quote footer{font-size:1rem;line-height:1.5rem;font-style:normal}table{background:#fff;border:1px solid #adadad;border-collapse:collapse;display:block;margin:0 0 1rem;max-width:100%;overflow-y:hidden;overflow-x:auto;width:100%!important}table th{vertical-align:bottom}table td{vertical-align:top}table td,table th{border:1px solid #adadad;padding:.5rem;text-align:left}table td:first-child,table th:first-child{border-left:0}table td:last-child,table th:last-child{border-right:0}table td p,table th p{margin-top:0}table :not(thead)+tbody tr:first-child th,table tbody tr:first-child th,table thead tr:first-child th{border-top:0}table tbody tr:last-child td{border-bottom:0}table tbody tr:nth-child(2n)>td{background-color:#e9e9e9}html{overflow-x:visible;scroll-behavior:smooth}@media(prefers-reduced-motion){html{scroll-behavior:auto}}body{font-family:Lato,Trebuchet MS,Roboto,Helvetica Neue,Helvetica,Arial,sans-serif;position:relative}.visually-hidden{position:absolute;overflow:hidden;clip:rect(0 0 0 0);height:1px;width:1px;margin:-1px;padding:0;border:0}#content-start:focus{outline:none}footer{margin-top:0!important}@supports((position:-webkit-sticky) or (position:sticky)){.Layout-module--main--1OIFf{position:relative;padding-bottom:4rem}}.stacked-nav{background:#fff;border:1px solid #adadad;margin:0 0 2em}@media print{.stacked-nav{display:none!important}}.stacked-nav__root{font-size:1rem;line-height:1.5rem;border-bottom:1px solid #adadad;font-weight:700;margin:0;max-width:none;position:relative;text-decoration:none}.stacked-nav__root a{color:#222}.stacked-nav__root--no-link{padding:.5em}.stacked-nav__hint{color:#222;display:block}.stacked-nav__hint :active{color:#fff}.stacked-nav__list{list-style:none;margin:0;max-width:100%;padding:0}.stacked-nav__list-item{border-top:1px solid #adadad}.stacked-nav__content-wrapper{display:block}.stacked-nav a{color:#005ea5;display:block;padding:.5em;position:relative;text-decoration:none}.stacked-nav a[aria-current=page],.stacked-nav a[aria-current=true]{background:#e9e9e9;font-weight:700}.stacked-nav a[aria-current=page]:before,.stacked-nav a[aria-current=true]:before{background:#004650;content:"";display:block;height:100%;left:0;position:absolute;top:0;width:.25em}.stacked-nav a:hover{background:#d6d6d6}.stacked-nav a:active{background:#004650;color:#fff}.stacked-nav a:active span{color:#fff}.stacked-nav__nested{list-style:none;margin:0;padding:0}.stacked-nav__nested .stacked-nav__content-wrapper{padding-left:1rem!important}.stacked-nav__nested ul .stacked-nav__content-wrapper{padding-left:2rem!important}.TopicChaptersMenu-module--toggleButton--2MGXA{-webkit-appearance:none;-moz-appearance:none;appearance:none;background:#e9e9e9;border:1px solid #adadad;color:#005ea5;cursor:pointer;display:block;margin:0 0 2rem;padding:1rem 2rem 1rem .5rem;position:relative;text-align:left;width:100%}.TopicChaptersMenu-module--toggleButton--2MGXA:focus{outline:.25rem solid #0092a6;z-index:1}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=false]+.stacked-nav{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]{border-bottom:0;margin:0}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded=true]+.stacked-nav{display:block}@media(min-width:37.5em){.TopicChaptersMenu-module--toggleButton--2MGXA{display:none}.TopicChaptersMenu-module--toggleButton--2MGXA[aria-expanded]+.stacked-nav{display:block}}.TopicChaptersMenu-module--icon--27uSj{color:#005ea5;right:.5rem;position:absolute;top:50%;-webkit-transform:translateY(-50%);transform:translateY(-50%)}.ChapterContents-module--wrapper--3ONbu{position:relative}.ChapterContents-module--printBtn--Rk_Zs{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;bottom:100%;cursor:pointer;display:none;padding:0}.ChapterContents-module--printBtn--Rk_Zs:visited{color:#4c2c92}.ChapterContents-module--printBtn--Rk_Zs:hover{color:#2e8aca}.ChapterContents-module--printBtn--Rk_Zs:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterContents-module--printBtn--Rk_Zs:active{color:#222}.ChapterContents-module--printBtn--Rk_Zs svg{font-size:1.25rem;line-height:1.75rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterContents-module--printBtn--Rk_Zs:hover svg{color:#2e8aca}@media(min-width:37.5em){.ChapterContents-module--wrapper--3ONbu:after,.ChapterContents-module--wrapper--3ONbu:before{content:" ";display:table}.ChapterContents-module--wrapper--3ONbu:after{clear:both}.ChapterContents-module--menu--3Epka{float:left;margin-right:1rem;width:-webkit-calc(25% - .5rem);width:calc(25% - .5rem)}.ChapterContents-module--landing--3klSq,.ChapterContents-module--onThisPage--1333P{float:right;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + .5rem);overflow:hidden;width:-webkit-calc(75% - .5rem);width:calc(75% - .5rem)}}@media(min-width:56.25em){.ChapterContents-module--printBtn--Rk_Zs{display:block;margin-bottom:3rem;position:absolute;right:0}.ChapterContents-module--menu--3Epka{margin-right:2rem;width:-webkit-calc(25% - 1rem);width:calc(25% - 1rem)}.ChapterContents-module--landing--3klSq{width:-webkit-calc(75% - 1rem);width:calc(75% - 1rem)}.ChapterContents-module--onThisPage--1333P{position:-webkit-sticky;position:sticky;top:0;width:-webkit-calc(16.66667% - 1rem);width:calc(16.66667% - 1rem)}.ChapterContents-module--body--1XBoo{margin-left:calc(25% + 1rem);width:-webkit-calc(58.33333% - 2rem);width:calc(58.33333% - 2rem)}}@media print{.ChapterContents-module--menu--3Epka,.ChapterContents-module--onThisPage--1333P,.ChapterContents-module--printBtn--Rk_Zs{display:none}.ChapterContents-module--body--1XBoo{width:100%}}.ChapterBody-module--wrapper--2HCfk>.visually-hidden:first-child+*>:first-child{margin-top:0}.ChapterBody-module--wrapper--2HCfk h2:focus,.ChapterBody-module--wrapper--2HCfk h3:focus,.ChapterBody-module--wrapper--2HCfk h4:focus,.ChapterBody-module--wrapper--2HCfk h5:focus,.ChapterBody-module--wrapper--2HCfk h6:focus{outline:0!important}.ChapterBody-module--basisWrapper--3JBM_{border:1px solid #adadad;margin-top:1rem;max-width:66ch}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-top:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK{padding:0 1rem 1rem}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK>:last-child{margin-bottom:0}.ChapterBody-module--headerWrapper--qSIFw{padding:1rem;position:relative}.ChapterBody-module--toggleBtn--3g0p7{color:#005ea5;-webkit-tap-highlight-color:rgba(0,146,166,.333);text-decoration:underline;-webkit-text-decoration-skip:ink;text-decoration-skip-ink:auto;-webkit-appearance:none;-moz-appearance:none;appearance:none;background:none;border:0;cursor:pointer;display:block;margin-top:-.5rem;padding:0}.ChapterBody-module--toggleBtn--3g0p7:visited{color:#4c2c92}.ChapterBody-module--toggleBtn--3g0p7:hover{color:#2e8aca}.ChapterBody-module--toggleBtn--3g0p7:focus{outline:.25rem solid #0092a6;color:#005ea5}.ChapterBody-module--toggleBtn--3g0p7:active{color:#222}.ChapterBody-module--toggleBtn--3g0p7:after{content:"";height:100%;left:0;position:absolute;top:0;width:100%}.ChapterBody-module--toggleBtn--3g0p7 svg{font-size:1.125rem;line-height:1.5rem;color:#0e0e0e;margin-right:.5rem;vertical-align:text-bottom}.ChapterBody-module--toggleBtn--3g0p7:hover svg{color:#2e8aca}.ChapterBody-module--body--2n0CK[aria-hidden=true]{display:none}@media print{.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--headerWrapper--qSIFw>:first-child{margin-bottom:0}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--body--2n0CK[aria-hidden=true]{display:block}.ChapterBody-module--basisWrapper--3JBM_ .ChapterBody-module--toggleBtn--3g0p7{display:none}}.ChapterOnThisPage-module--wrapper--2zc7n{margin-bottom:2rem}.ChapterOnThisPage-module--heading--2SdDN{margin-top:0}.ChapterOnThisPage-module--rootList--2II70{list-style:disc}.ChapterOnThisPage-module--subList--Pwxy9{list-style:circle}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:none}@media(min-width:56.25em){.ChapterOnThisPage-module--heading--2SdDN{font-size:1.25rem;line-height:1.75rem;margin-bottom:1rem;margin-top:0}@supports((position:-webkit-sticky) or (position:sticky)){.ChapterOnThisPage-module--rootList--2II70 a[aria-current=location]{font-weight:700}.ChapterOnThisPage-module--rootList--2II70 a:focus+.ChapterOnThisPage-module--subList--Pwxy9{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--subList--Pwxy9{clip:rect(0,0,0,0);height:1px;overflow:hidden;position:absolute!important;width:1px}.ChapterOnThisPage-module--subList--Pwxy9:focus-within{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--expandedSubList--1m1WN{clip:auto;height:auto;overflow:visible;position:static!important;width:auto}.ChapterOnThisPage-module--basisForRecs--1xLSs{display:list-item}}}</style><link rel="sitemap" type="application/xml" href="../../../../sitemap.xml"/><title data-react-helmet="true">Scenario: NSAIDs  prescribing issues | Management | NSAIDs - prescribing issues | CKS | NICE</title><link data-react-helmet="true" rel="search" type="application/opensearchdescription+xml" href="../../../../opensearch.xml" title="CKS"/><link data-react-helmet="true" rel="icon" href="../../../../favicon.ico"/><link data-react-helmet="true" rel="canonical" href="index.html"/><meta data-react-helmet="true" name="description" content="Covers factors that need to be considered when prescribing a nonsteroidal anti-inflammatory drug (NSAID)."/><meta data-react-helmet="true" property="og:description" content="Covers factors that need to be considered when prescribing a nonsteroidal anti-inflammatory drug (NSAID)."/><meta data-react-helmet="true" property="og:url" content="https://cks.nice.org.uk/topics/nsaids-prescribing-issues/management/nsaids-prescribing-issues/"/><meta data-react-helmet="true" property="og:locale" content="en_GB"/><meta data-react-helmet="true" property="og:type" content="website"/><meta data-react-helmet="true" property="og:title" content="Scenario: NSAIDs  prescribing issues | Management | NSAIDs - prescribing issues | CKS | NICE"/><meta data-react-helmet="true" property="og:image" content="https://cks.nice.org.uk/open-graph-image.png"/><meta data-react-helmet="true" property="og:image:width" content="1200"/><meta data-react-helmet="true" property="og:image:height" content="630"/><meta data-react-helmet="true" name="twitter:card" content="summary"/><meta data-react-helmet="true" name="twitter:image" content="https://cks.nice.org.uk/twitter-summary-image.png"/><meta data-react-helmet="true" name="twitter:image:alt" content="NICE and CKS logos"/><meta data-react-helmet="true" name="twitter:site" content="@NICEcomms"/><meta data-react-helmet="true" name="twitter:creator" content="@NICEcomms"/><meta data-react-helmet="true" name="theme-color" content="#004650"/><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+'';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer', 'GTM-54QC4NL');</script><link rel="manifest" href="../../../../manifest.webmanifest" crossorigin="anonymous"/><meta name="theme-color" content="#004650"/><link rel="apple-touch-icon" sizes="48x48" href="../../../../icons/icon-48x48.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="72x72" href="../../../../icons/icon-72x72.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="96x96" href="../../../../icons/icon-96x96.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="144x144" href="../../../../icons/icon-144x144.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="192x192" href="../../../../icons/icon-192x192.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="256x256" href="../../../../icons/icon-256x256.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="384x384" href="../../../../icons/icon-384x384.png@v=28734348209eeeae5c03a37867f1beb1"/><link rel="apple-touch-icon" sizes="512x512" href="../../../../icons/icon-512x512.png@v=28734348209eeeae5c03a37867f1beb1"/><link as="script" rel="preload" href="../../../../webpack-runtime-28c424ef71f39faedaf0.js"/><link as="script" rel="preload" href="../../../../framework-34da02e39e1f104d9937.js"/><link as="script" rel="preload" href="../../../../app-53a71c38b210970893c4.js"/><link as="script" rel="preload" href="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js"/><link as="script" rel="preload" href="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js"/><link as="script" rel="preload" href="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"/><link as="fetch" rel="preload" href="../../../../page-data/topics/nsaids-prescribing-issues/management/nsaids-prescribing-issues/page-data.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/sq/d/3666801979.json" crossorigin="anonymous"/><link as="fetch" rel="preload" href="../../../../page-data/app-data.json" crossorigin="anonymous"/><script src="https://cdn.nice.org.uk/cookie-banner/cookie-banner.min.js" type="text/javascript" async=""></script></head><body><noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54QC4NL" height="0" width="0" style="display: none; visibility: hidden" aria-hidden="true"></iframe></noscript><div id="___gatsby"><div style="outline:none" tabindex="-1" id="gatsby-focus-wrapper"><div><div class="Header-module--header--3os44"><header aria-label="Site header"><ul class="SkipLinks-module--list--1WwLa" aria-label="Accessibility links"><li><a href="index.html#content-start" class="SkipLinks-module--link--hkZw8">Skip to content</a></li><li><a href="https://www.nice.org.uk/accessibility" class="SkipLinks-module--link--hkZw8">Accessibility help</a></li></ul><div class="Header-module--container--1mfIr"><a href="https://www.nice.org.uk/" aria-label="Home" class="Header-module--home--1TCPb"><svg viewBox="0 0 4616 512" fill="none" class="Header-module--icon--4LSt5" aria-hidden="true" focusable="false"><path d="M1626 44v175h-22L1497 71v148h-19V44h22l107 147V44h19zm130 154a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-35 18-48 11-14 27-20 47-20 19 0 34 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm109 16V104h-27V87h27V40h19v47h30v17h-30v115h-19zm88-180v26h-21V39h21zm-20 48h20v132h-20V87zm107-2c20 0 35 6 48 20 11 12 17 28 17 48 0 19-6 36-17 48a61 61 0 01-48 20c-19 0-35-7-47-20a69 69 0 01-17-48c0-20 5-36 17-48 12-14 28-20 47-20zm0 118c14 0 25-5 34-15 7-9 11-21 11-35s-4-26-11-35c-9-10-20-15-34-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm107-116v21c5-7 11-12 18-17 6-4 14-6 23-6 8 0 16 1 22 4 6 2 12 6 17 11 10 10 16 24 16 42v77h-20v-76c0-13-3-22-10-29-7-8-16-11-26-11a38 38 0 00-40 40v76h-19V87h19zm222 111a52 52 0 01-46 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 5-35 17-48 12-14 27-20 47-20 19 0 35 8 45 23V87h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-34 15c-8 9-12 21-12 35s4 26 12 35c9 10 20 15 34 15zm114 16h-19V34h19v185zm108 0h-19V44h19v175zm55-132v21c5-7 10-12 17-17 7-4 15-6 23-6 9 0 17 1 23 4 6 2 12 6 16 11 11 10 16 24 16 42v77h-19v-76c0-13-4-22-10-29-7-8-16-11-27-11a38 38 0 00-39 40v76h-19V87h19zm202 35c-2-13-13-20-33-20s-30 6-30 19c0 5 2 9 6 12 5 2 10 5 16 6l21 5 21 7c7 2 12 6 16 11 5 5 7 11 7 19 0 13-5 23-15 30-9 7-22 10-38 10-18 0-32-4-42-13-9-8-14-18-15-31h20c2 13 8 21 21 25l13 2 13-1 11-3c8-3 12-9 12-17 0-5-2-9-6-12s-10-6-16-7l-21-5-21-7c-7-2-12-6-16-10-4-5-6-11-6-19 0-12 4-22 12-28 9-7 22-10 39-10 15 0 28 4 37 11 8 7 12 16 14 26h-20zm60 97V104h-26V87h26V40h20v47h30v17h-30v115h-20zm89-180v26h-21V39h21zm-21 48h20v132h-20V87zm65 132V104h-26V87h26V40h20v47h30v17h-30v115h-20zm162 0v-21c-4 7-10 12-17 16-7 5-14 7-23 7s-16-1-22-4c-7-2-12-6-17-11a57 57 0 01-16-42V87h20v76c0 12 3 22 10 29 6 7 15 11 26 11a39 39 0 0039-40V87h20v132h-20zm65 0V104h-26V87h26V40h20v47h30v17h-30v115h-20zm124-16c17 0 30-7 37-22h22c-5 12-12 22-22 29-9 7-22 11-38 11-19 0-35-7-47-20a68 68 0 01-18-48c0-20 5-36 17-48 12-14 28-20 47-20 20 0 35 6 48 20 11 12 17 28 17 48v8h-109c1 12 6 22 14 30s19 12 32 12zm-2-100c-12 0-22 4-30 11s-12 17-14 28h88c-1-11-6-21-14-28s-18-11-30-11zm195-52c-9 0-16 2-21 6-4 4-7 11-7 20v10h30v17h-30v115h-19V104h-23V87h23V75c0-14 4-25 12-32 9-7 21-11 36-11h1v19h-2zm75 34c19 0 35 6 47 20 12 12 18 28 18 48 0 19-6 36-18 48a61 61 0 01-47 20c-19 0-35-7-47-20a69 69 0 01-18-48c0-20 6-36 18-48 12-14 28-20 47-20zm0 118c14 0 25-5 33-15 8-9 12-21 12-35s-4-26-12-35c-8-10-19-15-33-15s-25 5-33 15c-8 9-12 21-12 35s4 26 12 35c8 10 19 15 33 15zm156-118v20h-2c-14 0-25 5-34 17-9 11-13 24-13 39v58h-19V87h19v32c4-13 13-23 27-30 6-3 13-4 21-4h1zM1617 293v175h-19v-78h-101v78h-19V293h19v78h101v-78h19zm91 159c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c1 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm187 95a52 52 0 01-47 23c-18 0-34-7-45-20a70 70 0 01-18-48c0-19 6-36 18-49 11-13 27-19 47-19 19 0 34 7 45 23v-21h20v132h-20v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm114 16h-19V283h19v185zm46 0V353h-27v-17h27v-48h19v48h30v17h-30v115h-19zm87-185v73l17-16c7-4 15-6 24-6 8 0 16 1 22 3a58 58 0 0133 54v77h-20v-77c0-12-3-21-10-29-7-7-16-10-26-10a39 39 0 00-40 40v76h-19V283h19zm280 164a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm109-116v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 11 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10a39 39 0 00-39 40v76h-19V336h19zm222 111a52 52 0 01-47 23c-19 0-34-7-46-20a71 71 0 01-17-48c0-19 6-36 17-49 12-13 28-19 47-19 20 0 35 7 46 23v-74h19v185h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm233-1a56 56 0 0053-36h21c-6 17-15 30-28 39a82 82 0 01-50 16c-25 0-46-9-61-26a92 92 0 01-22-64c0-25 7-46 22-63 15-18 36-26 61-26a78 78 0 0178 54h-21c-4-11-11-19-20-25-10-7-20-10-33-10-12 0-22 2-30 5-9 4-15 9-21 15a73 73 0 00-17 50c0 21 6 37 17 50 12 14 29 21 51 21zm198-4a52 52 0 01-47 23c-19 0-34-7-46-20a70 70 0 01-17-48c0-19 6-36 17-49 12-13 28-19 48-19 19 0 34 7 45 23v-21h19v132h-19v-21zm-44 5c14 0 25-5 33-15 8-9 12-21 12-35 0-15-4-26-12-36s-19-14-33-14-25 4-34 14c-8 10-12 21-12 36 0 14 4 26 12 35 9 10 20 15 34 15zm163-118v19h-2c-14 0-26 6-34 18-9 10-13 23-13 39v58h-19V336h19v32c4-14 13-24 27-30 6-3 13-4 21-4h1zm73 118c18 0 31-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-19 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 18-49s27-19 47-19c19 0 35 6 47 19s17 29 17 49v8h-109c2 12 7 22 15 30s19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm162-40v59h96v19h-96v59h108v19h-127V293h127v19h-108zm189 88l51 68h-25l-37-54-37 54h-25l51-68-48-64h25l34 50 33-50h25l-47 64zm120 52c9 0 16-3 23-7 6-5 11-11 14-19h21c-4 13-12 24-22 32-11 8-24 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19a60 60 0 0161 44h-20c-3-8-8-15-14-19-7-5-14-7-23-7-8 0-15 1-21 4-6 2-10 6-14 10-9 10-13 22-13 36s4 26 13 35c8 10 20 15 35 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-22 11-38 11-20 0-35-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 13-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 19 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-14 28h88c-2-11-6-21-14-28-8-8-18-11-30-11zm105 116h-19V283h19v185zm51 0h-20V283h20v185zm89-16c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19 11 13 17 29 17 49v8h-109c2 12 6 22 14 30 9 8 19 12 32 12zm-1-100c-12 0-22 3-31 11-7 7-12 17-14 28h89c-2-11-7-21-14-28-8-8-18-11-30-11zm105-16v20c5-6 10-11 17-16 7-4 15-6 23-6 9 0 17 1 23 3 6 3 12 6 16 11 11 11 16 25 16 43v77h-19v-77c0-12-4-21-10-29-7-7-16-10-27-10s-20 3-28 11c-7 7-11 17-11 29v76h-19V336h19zm185 116a40 40 0 0037-26h21c-4 13-12 24-22 32-11 8-25 12-40 12-19 0-34-7-46-20a69 69 0 01-18-48c0-20 6-36 18-49s27-19 46-19c15 0 29 4 40 12 10 8 18 18 22 31h-21c-3-7-8-14-15-18-6-5-13-7-22-7-8 0-15 1-21 4-6 2-11 6-15 10-8 10-12 22-12 36s4 26 12 35c9 10 21 15 36 15zm137 0c18 0 30-8 38-22h21c-4 12-11 21-21 29-10 7-23 11-38 11-20 0-36-7-48-20a68 68 0 01-18-48c0-20 6-36 17-49 12-13 28-19 48-19 19 0 35 6 47 19s17 29 17 49v8h-109c2 12 6 22 15 30 8 8 18 12 31 12zm-1-100c-12 0-22 3-30 11-8 7-13 17-15 28h89c-2-11-6-21-14-28-8-8-18-11-30-11zM412 454c0 16-7 19-18 19h-53c-11 0-20-4-27-13L130 213h-2v242c0 13-6 18-18 18H52c-14 0-20-3-20-18V62c0-16 7-19 20-19h52c13 0 19 3 26 13l184 248h1V61c0-14 7-18 19-18h60c16 0 17 8 17 19v392h1zm197 4c0 7-5 14-14 14h-71c-9 0-14-7-14-14V56c0-8 5-15 14-15h71c9 0 14 7 14 14v403zm415-380l-18 52c-2 6-5 9-9 9l-8-2c-33-16-58-21-87-21-65 0-106 49-106 140 0 98 47 140 107 140 29 0 55-5 84-17l9-3c6 0 9 3 11 10l16 46 2 10c0 6-3 11-12 14-42 16-77 24-125 24-131 0-197-87-197-221S772 32 896 32c45 0 82 9 118 25 9 4 12 8 12 12l-2 9zm336-37c13 0 17 6 16 15l-6 50c-1 13-9 15-24 15h-149v93h140c14 0 19 7 19 17v45c0 12-7 18-18 18h-141v98h161c11 0 18 5 18 17v46c0 11-6 17-17 17h-240c-14 0-21-4-21-19V59c0-11 6-18 16-18h246z" fill="currentColor"></path></svg></a><div class="Header-module--wrapper--2e13D"><div class="Header-module--search--2nfnz"><form id="global-nav-search-form" role="search" action="https://cks.nice.org.uk/search" class="Search-module--search--2wNll"><label class="Search-module--label--1rrog" for="autocomplete">Search CKS…</label><div class="Autocomplete-module--ac--2PqiF"><div class="autocomplete__wrapper"><input type="search" id="autocomplete" name="q" class="autocomplete__input autocomplete__input--default" placeholder="Search CKS…" data-hj-allow="" maxLength="512" value=""/></div></div><button class="Search-module--button--2FbnI" type="submit" aria-label="Perform search"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="Search-module--icon--2JB42" aria-hidden="true" focusable="false"><path d="M83.784 476.472L197.112 363.16c30.144 20.32 65.056 30.528 100.032 30.528 45.904 0 91.776-17.488 126.8-52.528 70.064-70.064 70.064-183.584 0-253.616C388.936 52.504 343.048 35 297.144 35c-45.904 0-91.808 17.504-126.848 52.528-61.696 61.696-68.976 157.12-21.968 226.864L35 427.752l48.784 48.72zm213.36-137.952c-33.168 0-64.352-12.896-87.792-36.368-48.416-48.448-48.416-127.2 0-175.616 23.44-23.44 54.64-36.352 87.792-36.352s64.336 12.912 87.776 36.368c23.44 23.456 36.384 54.64 36.384 87.792s-12.928 64.352-36.384 87.792c-23.456 23.472-54.624 36.368-87.776 36.368v.016z" fill="currentColor"></path></svg></button></form></div><button class="Header-module--mobileMenuBtn--1LgyL" id="header-menu-button" type="button" aria-controls="header-menu" aria-expanded="false" aria-haspopup="menu" aria-label="Expand site menu">Menu</button></div></div><div id="header-menu" class="Nav-module--wrapper--2_xng Nav-module--wrapperWithSubLinks--3PUfX"><nav class="Nav-module--nav--2aQpa" aria-label="primary navigation"><div class="Nav-module--menuWrapper--2fp8S"><ul class="Nav-module--menuList--264L-" aria-labelledby="header-menu-button"><li><a href="https://pathways.nice.org.uk/" class="Nav-module--link--3JzDA">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Nav-module--link--3JzDA">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Nav-module--link--3JzDA">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Nav-module--link--3JzDA">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary">BNF<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Nav-module--link--3JzDA"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Nav-module--link--3JzDA"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Nav-module--visuallyHidden--ORHqX">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Nav-module--tooltip--1Uj-W">Clinical Knowledge Summaries</span></a><div class="SubNav-module--wrapper--yAXWY"><ul class="SubNav-module--list--1K9bK" aria-label="CKS links"><li class="SubNav-module--imageLink--3xwIS"><a href="../../../../index.html" class="SubNav-module--link--39i23" aria-label="CKS - Home"><img src="data:image/svg+xml;base64,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" class="SubNav-module--image--uq-a2" alt=""/></a></li><li><a href="../../../index.html" class="SubNav-module--link--39i23" aria-label="Health topics A to Z">Health topics A to Z</a></li><li><a href="../../../../specialities/index.html" class="SubNav-module--link--39i23" aria-label="Specialities">Specialities</a></li><li><a href="../../../../whats-new/index.html" class="SubNav-module--link--39i23" aria-label="What&#x27;s new">What&#x27;s new</a></li><li><a href="../../../../about/index.html" class="SubNav-module--link--39i23" aria-label="About CKS">About CKS</a></li></ul></div></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Nav-module--link--3JzDA">Journals and databases</a></li></ul></div></nav></div></header><aside class="CoronaMessage-module--wrapper--zRiaV" aria-label="COVID-19 Notice"><div class="CoronaMessage-module--container--36Biz"><p>Read about<!-- --> <a href="https://www.nice.org.uk/covid-19">our approach to COVID-19</a></p></div></aside></div></div><main class="Layout-module--main--1OIFf" id="content-start"><div class="container"><nav aria-label="Breadcrumbs" role="navigation"><ol class="breadcrumbs"><li class="breadcrumbs__crumb"><a href="https://www.nice.org.uk/">NICE</a></li><li class="breadcrumbs__crumb"><a href="../../../../index.html">CKS</a></li><li class="breadcrumbs__crumb"><a href="../../../index.html">Health topics A to Z</a></li><li class="breadcrumbs__crumb"><a href="../../index.html">NSAIDs - prescribing issues</a></li><li class="breadcrumbs__crumb"><a href="../index.html">Management</a></li><li class="breadcrumbs__crumb"><span>Scenario: NSAIDs  prescribing issues</span></li></ol></nav><script type="application/ld+json">{"@context":"http://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.nice.org.uk/","name":"NICE"}},{"@type":"ListItem","position":2,"item":{"@id":"/","name":"CKS"}},{"@type":"ListItem","position":3,"item":{"@id":"/topics/","name":"Health topics A to Z"}},{"@type":"ListItem","position":4,"item":{"@id":"/topics/nsaids-prescribing-issues/","name":"NSAIDs - prescribing issues"}},{"@type":"ListItem","position":5,"item":{"@id":"/topics/nsaids-prescribing-issues/management/","name":"Management"}},{"@type":"ListItem","position":6,"item":{"name":"Scenario: NSAIDs  prescribing issues"}}]}</script><div class="page-header"><h1 class="page-header__heading"><span class="page-header__pre-heading">NSAIDs - prescribing issues: </span><span>Scenario: NSAIDs – prescribing issues</span></h1><p class="page-header__lead"><span>Last revised in April 2020</span></p></div><p class="visually-hidden">Covers factors that need to be considered when prescribing a nonsteroidal anti-inflammatory drug (NSAID).</p><div class="ChapterContents-module--wrapper--3ONbu"><div class="ChapterContents-module--menu--3Epka"><nav class="stacked-nav" aria-label="NSAIDs - prescribing issues chapters"><ul class="stacked-nav__list"><li class="stacked-nav__list-item" data-tracking="Summary"><a aria-current="false" href="../../index.html"><span class="stacked-nav__content-wrapper">Summary</span></a></li><li class="stacked-nav__list-item" data-tracking="Have I got the right topic?"><a aria-current="false" href="../../have-i-got-the-right-topic/index.html"><span class="stacked-nav__content-wrapper">Have I got the right topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="How up-to-date is this topic?"><a aria-current="false" href="../../how-up-to-date-is-this-topic/index.html"><span class="stacked-nav__content-wrapper">How up-to-date is this topic?</span></a></li><li class="stacked-nav__list-item" data-tracking="Goals and outcome measures"><a aria-current="false" href="../../goals-outcome-measures/index.html"><span class="stacked-nav__content-wrapper">Goals and outcome measures</span></a></li><li class="stacked-nav__list-item" data-tracking="Background information"><a aria-current="false" href="../../background-information/index.html"><span class="stacked-nav__content-wrapper">Background information</span></a></li><li class="stacked-nav__list-item" data-tracking="Management"><a aria-current="false" href="../index.html"><span class="stacked-nav__content-wrapper">Management</span></a><ul class="stacked-nav__nested"><li class="stacked-nav__list-item" data-tracking="Management | Scenario: NSAIDs  prescribing issues"><a aria-current="true" class="" href="index.html"><span class="stacked-nav__content-wrapper">Scenario: NSAIDs  prescribing issues</span></a></li></ul></li><li class="stacked-nav__list-item" data-tracking="Supporting evidence"><a aria-current="false" href="../../supporting-evidence/index.html"><span class="stacked-nav__content-wrapper">Supporting evidence</span></a></li><li class="stacked-nav__list-item" data-tracking="How this topic was developed"><a aria-current="false" href="../../how-this-topic-was-developed/index.html"><span class="stacked-nav__content-wrapper">How this topic was developed</span></a></li><li class="stacked-nav__list-item" data-tracking="References"><a aria-current="false" href="../../references/index.html"><span class="stacked-nav__content-wrapper">References</span></a></li></ul></nav></div><div class="ChapterContents-module--onThisPage--1333P"><nav class="ChapterOnThisPage-module--wrapper--2zc7n" aria-labelledby="on-this-page"><h2 class="ChapterOnThisPage-module--heading--2SdDN" id="on-this-page">On this page</h2><ol class="ChapterOnThisPage-module--rootList--2II70" aria-label="Jump links to section on this page"><li><a href="index.html#initiating-nsaids">Initiating NSAIDs</a><ol aria-label="Sections within Initiating NSAIDs" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-89c">Basis for recommendation</a></li></ol></li><li><a href="index.html#contraindications">Contraindications</a><ol aria-label="Sections within Contraindications" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-e23">Basis for recommendation</a></li></ol></li><li><a href="index.html#adverse-effects">Adverse effects</a><ol aria-label="Sections within Adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-997">Basis for recommendation</a></li></ol></li><li><a href="index.html#cardiovascular-renal-adverse-effects">Cardiovascular and renal adverse effects</a><ol aria-label="Sections within Cardiovascular and renal adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#managing-risk">Managing risk</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-4f8">Basis for recommendation</a></li></ol></li><li><a href="index.html#gastrointestinal-adverse-effects">Gastrointestinal adverse effects</a><ol aria-label="Sections within Gastrointestinal adverse effects" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class=""><a href="index.html#managing-risk">Managing risk</a></li><li class=""><a href="index.html#proton-pump-inhibitor-doses-for-gastroprotection">Proton pump inhibitor doses for gastroprotection</a></li><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-642">Basis for recommendation</a></li></ol></li><li><a href="index.html#drug-interactions">Drug interactions</a><ol aria-label="Sections within Drug interactions" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-ed3">Basis for recommendation</a></li></ol></li><li><a href="index.html#monitoring">Monitoring</a><ol aria-label="Sections within Monitoring" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-a0a">Basis for recommendation</a></li></ol></li><li><a href="index.html#conception">Conception</a><ol aria-label="Sections within Conception" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-860">Basis for recommendation</a></li></ol></li><li><a href="index.html#pregnancy">Pregnancy</a><ol aria-label="Sections within Pregnancy" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-510">Basis for recommendation</a></li></ol></li><li><a href="index.html#breastfeeding">Breastfeeding</a><ol aria-label="Sections within Breastfeeding" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-dd5">Basis for recommendation</a></li></ol></li><li><a href="index.html#advice">Advice</a><ol aria-label="Sections within Advice" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-9e4">Basis for recommendation</a></li></ol></li><li><a href="index.html#covid-19">COVID-19</a><ol aria-label="Sections within COVID-19" class="ChapterOnThisPage-module--subList--Pwxy9 "><li class="ChapterOnThisPage-module--basisForRecs--1xLSs"><a href="index.html#basis-for-recommendation-de6">Basis for recommendation</a></li></ol></li></ol></nav></div><div class="ChapterContents-module--body--1XBoo"><section aria-labelledby="nsaids-prescribing-issues" class="ChapterBody-module--wrapper--2HCfk "><h2 id="nsaids-prescribing-issues" class="visually-hidden">Scenario: NSAIDs – prescribing issues</h2><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 1c41cab3-241a-4dc9-bc28-5e7554508570 --><!-- begin field c62f6910-0f8a-42ec-9ad7-acbd00893e6b --><p>From age 1 month onwards.</p><!-- end field c62f6910-0f8a-42ec-9ad7-acbd00893e6b --><!-- end item 1c41cab3-241a-4dc9-bc28-5e7554508570 --></div><section aria-labelledby="initiating-nsaids" class="ChapterBody-module--wrapper--2HCfk "><h3 id="initiating-nsaids">What should I consider when initiating NSAIDs?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 92f5cc57-79f5-4331-a91f-cad4dae17862 --><!-- begin field 35518a3a-43e8-4c6a-90e2-d1e59b49c7a0 --><ul><li>Prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) at the lowest effective dose for the shortest possible duration.</li><li>When prescribing NSAIDs, take into account the person's individual risk factors for <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a> and consider if:<ul><li>An alternative to an NSAID may be suitable, for example:<ul><li>A topical NSAID. </li><li>Physiotherapy, or referral for consideration of surgery.</li><li>A different oral analgesic (such as paracetamol, or an opioid).</li></ul></li><li>The person has any <a class="topic-reference internal-reference" href="index.html#contraindications">contraindications</a> to oral NSAIDs.</li><li>There are any potentially hazardous drug <a class="topic-reference internal-reference" href="index.html#drug-interactions">interactions</a>.</li><li>The person is already using an NSAID — for example, ibuprofen or aspirin purchased over-the-counter.</li><li>Gastroprotection is indicated. For example, because the person is:<ul><li>At increased risk of gastrointestinal adverse effects (for example, people that require long-term treatment).</li><li>Experiencing dyspepsia from standard NSAIDs.</li></ul></li><li>More frequent review and <a class="topic-reference internal-reference" href="index.html#monitoring">monitoring</a> for <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a> is required — for example, for people who are:<ul><li>At risk of multiple adverse effects (for example, the elderly, people with comorbidities).</li><li>Taking drugs which may interact with an NSAID. </li><li>At increased risk of gastrointestinal or <a class="topic-reference internal-reference" href="index.html#cardiovascular-renal-adverse-effects">cardiovascular or renal</a> adverse effects.</li></ul></li></ul></li></ul><!-- end field 35518a3a-43e8-4c6a-90e2-d1e59b49c7a0 --><!-- end item 92f5cc57-79f5-4331-a91f-cad4dae17862 --></div><section aria-labelledby="basis-for-recommendation-89c" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-89c">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 89c82b62-9758-45fd-aed3-1d3f576a0bc0 --><!-- begin field b322008c-00f8-40cc-a39f-16407a1f3ea0 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Osteoarthritis: care and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014a</a>], <em>Low back pain and sciatica</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016</a>], <em>Rheumatoid arthritis in adults: management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018b</a>], the key therapeutic topic <em>Non-steroidal anti-inflammatory drugs</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018a</a>], the European Medicines Agency (EMA) document <em>Questions and answers on the review of non-selective non-steroidal anti-inflammatory drugs (NSAIDs) and cardiovascular risk</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">EMA, 2012</a>], the European Society of Cardiology (ESC) review and position paper <em>Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>], and what CKS considers good clinical practice.</p><!-- end field b322008c-00f8-40cc-a39f-16407a1f3ea0 --><!-- end item 89c82b62-9758-45fd-aed3-1d3f576a0bc0 --></div></section></section><section aria-labelledby="contraindications" class="ChapterBody-module--wrapper--2HCfk "><h3 id="contraindications">Contraindications</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9d5c5687-30d1-4e5d-ac80-a20b2b2c931e --><!-- begin field e254915a-e4dc-4a04-8a4f-4549d921d81f --><ul><li><strong>Do not prescribe nonsteroidal anti-inflammatory drugs (NSAIDs) to people with:</strong><ul><li>Active gastrointestinal (GI) bleeding, or active GI ulcer.</li><li>A history of GI bleeding related to previous NSAID therapy, or a history of GI perforation related to previous NSAID therapy. </li><li>A history of recurrent GI haemorrhage (two or more distinct episodes), or history of recurrent GI ulceration (two or more distinct episodes).</li><li>A history of hypersensitivity/severe allergic reaction to an NSAID (including aspirin) — for example, asthma, rhinitis, angioedema or urticaria.</li><li>Severe heart failure.</li><li>Severe hepatic impairment — serum albumin less than 25 g/L or Child-Pugh score of 10 or more.</li><li>Severe renal impairment — estimated glomerular filtration rate (eGFR) less than 30 mL/minute/1.73 m<sup>2</sup>.</li></ul></li><li><strong>Do not prescribe COX-2 inhibitors, diclofenac, aceclofenac or high dose ibuprofen (more than 2400 mg daily)</strong> <strong>to people with</strong>:<ul><li>Ischaemic heart disease.</li><li>Inflammatory bowel disease (COX-2 inhibitors only).</li><li>Peripheral arterial disease.</li><li>Cerebrovascular disease.</li><li>Congestive heart failure (New York Heart Association [NYHA] classification II–IV).</li></ul></li><li><strong>Do not prescribe etoricoxib or high dose ibuprofen to</strong> people with uncontrolled hypertension (persistently above 140/90 mmHg).</li><li><strong>Prescribe NSAIDs with caution to people with:</strong><ul><li>A history of peptic ulceration (standard NSAIDs are contraindicated), or people at high risk of GI adverse effects (for example, the elderly).</li><li>Allergic disorders.  </li><li>Cardiac impairment, or heart failure — NSAIDs may impair renal function.</li><li>Cerebrovascular disease.</li><li>Coagulation disorders.</li><li>Connective-tissue disorders. </li><li>Hypertension — NSAIDs may impair renal function.</li><li>Inflammatory bowel disease — NSAIDs may increase the risk of developing or cause exacerbations of ulcerative colitis or Crohn's disease.</li><li>Ischaemic heart disease. </li><li>Peripheral arterial disease.</li><li>Risk factors for cardiovascular events — for example, hypertension, hyperlipidaemia, diabetes mellitus, smoking.</li><li>Hepatic impairment — dose reductions may be necessary.</li><li>Renal impairment (avoid if possible) — sodium and water retention may occur leading to a deterioration in renal function and, possibly renal failure. <ul><li>If the person cannot avoid using an NSAID and has impaired renal function, monitor creatinine clearance or eGFR. </li></ul></li></ul></li><li><strong>Also prescribe NSAIDs with caution in: </strong><ul><li>Women trying to conceive — NSAIDs may impair female fertility. </li><li>The elderly — increased risk of cardiovascular, renal, and serious GI adverse effects (including GI bleeding and perforation, which may be fatal).</li></ul></li><li>For detailed information on specific medicines, see the summary of product characteristics, available at the electronic Medicines Compendium (eMC) (<a href="http://www.medicines.org.uk/" data-hyperlink-id="d50c630d-14c2-4fb0-9267-a93100a0ab49">www.medicines.org.uk</a>).</li></ul><!-- end field e254915a-e4dc-4a04-8a4f-4549d921d81f --><!-- end item 9d5c5687-30d1-4e5d-ac80-a20b2b2c931e --></div><section aria-labelledby="basis-for-recommendation-e23" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-e23">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e23f49d2-ab91-47da-904a-8f65b2aad868 --><!-- begin field f6cf9888-5598-4bbe-93f8-9188e12c2d5d --><p>These recommendations are based on the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety updates <em>Diclofenac: new contraindications and warnings</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014</a>], and <em>Aceclofenac (Preservex): updated cardiovascular advice in line with diclofenac </em>and COX-2 inhibitors<em> </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015b</a>], the National Institute for Health and Care Excellence (NICE) key therapeutic topic <em>Non-steroidal anti-inflammatory drugs</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018a</a>], the <em>British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>], and the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>]. </p><ul><li>NICE recommends that people at risk of renal impairment or renal failure (particularly older people) should avoid NSAIDs if possible, as NSAIDs may rarely precipitate renal failure [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018a</a>]. </li></ul><!-- end field f6cf9888-5598-4bbe-93f8-9188e12c2d5d --><!-- end item e23f49d2-ab91-47da-904a-8f65b2aad868 --></div></section></section><section aria-labelledby="adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="adverse-effects">Adverse effects</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 90e7c6b9-4018-4d6b-9eee-4a60e041d5a5 --><!-- begin field 69ea7f61-3e51-435c-9773-433907e52217 --><ul><li><strong>The risks of adverse effects varies among individual nonsteroidal anti-inflammatory drugs (NSAIDs) and is influenced by the dose and duration of use.</strong><ul><li>Adverse effects may be minimized by using the lowest effective dose for the shortest duration necessary to control symptoms.</li></ul></li><li><strong>Dyspepsia and other upper gastrointestinal (GI) complications</strong> are the most common adverse effects of NSAIDs — for example, ulcer, perforation, obstruction or bleeding.<ul><li>People are at increased risk of serious NSAID–induced GI adverse events if they have one or more <a class="topic-reference internal-reference" href="index.html#gastrointestinal-adverse-effects">risk factor</a>. </li></ul></li><li><strong>Cardiovascular and renal complications</strong> are less common but serious NSAID adverse effects — for example, myocardial infarction, stroke, cardiac failure, hypertension, and renal failure.<ul><li>All NSAID use is associated with a small increased risk of thrombotic events independent of baseline cardiovascular risk factors or duration of NSAID use. However, the greatest risk may be in those receiving high doses long-term.</li><li>People with certain <a class="topic-reference internal-reference" href="index.html#cardiovascular-renal-adverse-effects">risk factors</a> have an increased risk of serious cardiac or renal adverse events.  </li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Prolonged bleeding (for example, after surgery) as a result of inhibition of platelet aggregation.</li><li>Bronchospasm — NSAIDs may exacerbate or precipitate asthma. Stop the NSAID if it is suspected to have precipitated bronchospasm.</li><li>Severe skin reactions and angioedema (for example, exfoliative dermatitis, Stevens-Johnson syndrome and toxic epidermal necrolysis) — stop the NSAID if these occur.</li><li>Anastomotic leakage. [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019</a>] </li><li>'Kounis syndrome' (allergic acute coronary syndrome). [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2019</a>] </li></ul></li><li><strong>Very rarely, NSAIDs can precipitate severe hepatic reactions </strong>(such as hepatitis, liver necrosis, or hepatic failure).<ul><li>If there are symptoms or signs of liver damage (for example, nausea, vomiting, abdominal pain, and jaundice), or persistently abnormal liver enzymes, stop the NSAID.</li></ul></li><li>For detailed information on specific medicines, see the summary of product characteristics, available at the electronic Medicines Compendium (eMC) (<a data-hyperlink-id="d50c630d-14c2-4fb0-9267-a93100a0ab49" href="http://www.medicines.org.uk/">www.medicines.org.uk</a>).</li></ul><!-- end field 69ea7f61-3e51-435c-9773-433907e52217 --><!-- end item 90e7c6b9-4018-4d6b-9eee-4a60e041d5a5 --></div><section aria-labelledby="basis-for-recommendation-997" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-997">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9979273a-1679-496c-a48f-0598fc69a93d --><!-- begin field 5deff959-04b2-4f0d-add9-c11c33f23d5b --><p>This information is based on the U.S. Food and Drug Administration (FDA) drug safety communication <em>FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FDA, 2015</a>], the European Society of Cardiology (ESC) review and position paper <em>Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>], the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>], and the <em>British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>]. </p><h5>NSAIDs and cardiovascular adverse effects</h5><ul><li>NSAIDs can increase the risk of heart attack or stroke in people with or without heart disease or risk factors for heart disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">FDA, 2015</a>].  <ul><li>However, in general, people with heart disease or risk factors for it have a greater likelihood of heart attack or stroke following NSAID use than people without these risk factors because they have a higher risk at baseline.</li></ul></li><li>All non-aspirin NSAIDs roughly double the risk of heart failure, and increase the risk of adverse effects in people with heart failure, including recurrent admission for myocardial infarction and dose-related excess mortality risk [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>]. <ul><li>Naproxen appears to have the least harmful cardiovascular risk profile, including in people with myocardial infarction or heart failure.</li></ul></li></ul><!-- end field 5deff959-04b2-4f0d-add9-c11c33f23d5b --><!-- end item 9979273a-1679-496c-a48f-0598fc69a93d --></div></section></section><section aria-labelledby="cardiovascular-renal-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="cardiovascular-renal-adverse-effects">What are the risk factors for cardiovascular and renal adverse effects?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 08988ebd-29b2-4d86-a142-c59146af551e --><!-- begin field 3b7668af-1293-49f9-b31d-a93b00de5ce8 --><ul><li><strong>Cardiovascular (CV) effects </strong><ul><li>Inhibition of COX-2 leads to suppression of prostacyclin (which normally protects endothelial cells, produces vasodilation and interacts with platelets to antagonize aggregation).</li><li>Inhibition of COX-1 inhibits conversion of arachidonic acid to thromboxane A2 (a potent platelet aggregator and vasoconstrictor). <ul><li>Selective COX-2 inhibition presents a CV risk, as it shifts the prothrombotic/antithrombotic balance and favours thrombosis. </li></ul></li></ul></li><li><strong>Renal effects </strong><ul><li>NSAIDs inhibit prostaglandins PGE2 and PGI2 synthesis which may result in sodium retention, reduced renal blood flow, and renal failure.</li></ul></li><li><strong>The risk for serious cardiac or renal adverse events </strong>(including myocardial infarction, heart failure, and hypertension) is increased in people with:<ul><li>Cerebrovascular disease. </li><li>Heart failure.</li><li>Ischaemic heart disease.</li><li>Peripheral arterial disease.</li><li>Renal impairment.</li></ul></li><li>People with risk factors for cardiovascular disease (for example, hypertension, hyperlipidaemia, diabetes mellitus, smoking) and all elderly people (aged 65 years or over) are also at increased risk. For more information, see the CKS topic on <a class="topic-reference external-reference" href="../../../cvd-risk-assessment-management/index.html">CVD risk assessment and management</a>.  </li></ul><!-- end field 3b7668af-1293-49f9-b31d-a93b00de5ce8 --><!-- end item 08988ebd-29b2-4d86-a142-c59146af551e --></div><section aria-labelledby="managing-risk" class="ChapterBody-module--wrapper--2HCfk "><h4 id="managing-risk">How should I manage the risk of cardiovascular and renal adverse effects?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a9194037-2e67-437f-a5cb-a96c00af6afe --><!-- begin field 19850688-cd0b-48de-9169-a96c00af6bda --><ul><li><strong>For people with heart failure:</strong><ul><li>Severe heart failure — do not prescribe nonsteroidal anti-inflammatory drugs (NSAIDs).</li><li>Mild to moderate heart failure — do not prescribe a COX-2 inhibitor, diclofenac, or high-dose ibuprofen (2400 mg or more daily). Prescribe a standard NSAID and <a class="topic-reference internal-reference" href="index.html#monitoring">monitor</a> the person closely.<ul><li>Ibuprofen up to 1200 mg daily, or naproxen up to 1000 mg daily are first-line options.</li></ul></li></ul></li><li><strong>For people with ischaemic heart disease, cerebrovascular disease, or peripheral arterial disease, prescribe:</strong><ul><li>Ibuprofen up to 1200 mg per day or naproxen up to 1000 mg daily are first-line options.<ul><li>COX-2 inhibitors, diclofenac, and high-dose ibuprofen are contraindicated.</li></ul></li></ul></li><li><strong>For people with severe renal impairment </strong><strong>(estimated glomerular filtration rate [eGFR] less than 30 mL/minute/1.73 m<sup>2</sup>):</strong><ul><li>Ideally, avoid prescribing NSAIDs.</li><li>If an NSAID is used, <a class="topic-reference internal-reference" href="index.html#monitoring">monitor</a> the person closely.</li></ul></li><li><strong>For people with risk factors for cardiovascular (CV) disease or the elderly, prescribe:</strong><ul><li>Ibuprofen up to 1200 mg per day or naproxen up to 1000 mg daily.<ul><li>Diclofenac should only be initiated after careful consideration of the associated risks in people with risk factors for CV disease.</li></ul></li></ul></li><li><strong>For people with hypertension:</strong><ul><li>Avoid prescribing etoricoxib or high-dose ibuprofen in people with uncontrolled hypertension (blood pressure persistently above 140/90 mmHg). </li><li>Consider whether <a class="topic-reference internal-reference" href="index.html#monitoring">monitoring</a> is needed.</li></ul></li></ul><!-- end field 19850688-cd0b-48de-9169-a96c00af6bda --><!-- end item a9194037-2e67-437f-a5cb-a96c00af6afe --></div></section><section aria-labelledby="basis-for-recommendation-4f8" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-4f8">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 4f8b5d82-ab2d-4da4-a989-a28a757b20e3 --><!-- begin field d29009a2-9e3d-46c0-b88a-582d256dede2 --><p>These recommendations are based on the Medicines and Healthcare products Regulatory Agency (MHRA) drug safety updates <em>Diclofenac: new contraindications and warnings </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014</a>], <em>High-dose ibuprofen (≥2400mg/day): small increase in cardiovascular risk </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015a</a>], <em>Cox-2 selective inhibitors and non-steroidal anti- inflammatory drugs (NSAIDs): Cardiovascular safety </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015c</a>], and <em>Non-steroidal anti-inflammatory drugs (NSAIDs): reminder on renal failure and impairment </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2009</a>], the European Society of Cardiology (ESC) review and position paper <em>Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>], the <em>British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>], the European Medicines Agency (EMA) review <em>Updated advice on the use of high-dose ibuprofen </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">EMA, 2015</a>], a U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) statement <em>FDA Approves labeling supplement for Celebrex (celecoxib) </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FDA, 2018</a>], the FDA drug safety communication <em>FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">FDA, 2015</a>], the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>], and expert opinion in a medical textbook <em>Medical Pharmacology at a glance</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Neal, 2015</a>].</p><h5>People at increased risk of cardiovascular events</h5><ul><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) can increase the risk of heart attack or stroke in people with or without heart disease, or risk factors for heart disease [<a class="bibliography-reference internal-reference" href="../../references/index.html">FDA, 2015</a>]. <ul><li>However, in general, people with heart disease or risk factors for it have a greater likelihood of heart attack or stroke following NSAID use than people without these risk factors, because they have a higher risk at baseline. </li></ul></li><li>All non-aspirin NSAIDs roughly double the risk of heart failure, and increase the risk of adverse effects in people with heart failure, including recurrent admission for myocardial infarction and dose-related excess mortality risk [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>]. </li></ul><h5>Increased risk of renal adverse effects</h5><ul><li>NSAIDs, including COX-2 inhibitors, may rarely precipitate renal failure, and vulnerable (particularly elderly) people may be at increased risk [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2009</a>].  </li><li>One case-controlled study of standard NSAIDs found that they increase the risk of acute renal failure 3-fold — ibuprofen was associated with a lower risk than diclofenac in this study [<a class="bibliography-reference internal-reference" href="../../references/index.html">Huerta et al, 2005</a>].</li><li>Four systematic reviews found increased risks of hypertension and elevated blood pressure (particularly systolic blood pressure) with NSAIDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Aw et al, 2005</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Zhang et al, 2006</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Morrison et al, 2007</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Chan et al, 2009</a>].</li><li>The Commission on Human Medicines concluded that etoricoxib, particularly at high doses, may be associated with more frequent and severe effects on blood pressure than other coxibs and standard NSAIDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">CSM, 2005</a>].</li></ul><h5>NSAIDS and cardiovascular (CV) risk profile</h5><ul><li>COX-2 inhibitors may be associated with an increased risk of cardiovascular problems such as heart attacks and strokes [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015c</a>]. </li><li>People taking 2400 mg or more of ibuprofen daily are at a higher risk of arterial thrombotic events (heart attack, stroke) than people taking placebo. This higher risk is similar to that seen with COX-2 inhibitors and diclofenac [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2015a</a>]. <ul><li>No increased risk of arterial thrombotic events is seen with ibuprofen at doses up to 1200 mg daily compared with not taking ibuprofen. There are limited data on the risk with ibuprofen at doses between 1200 mg and 2400 mg per day. It is uncertain whether such doses are associated with an increased cardiovascular risk compared with not taking ibuprofen.</li></ul></li><li>An EMA review also advised that data from meta-analyses and epidemiological studies confirmed a small increased risk of cardiovascular problems in people taking high doses of ibuprofen, and confirmed that there was no increased risk with ibuprofen doses up to 1200 mg daily [<a class="bibliography-reference internal-reference" href="../../references/index.html">EMA, 2015</a>].</li><li>Naproxen or low-dose ibuprofen are considered to have the most favourable thrombotic cardiovascular safety profiles of all non-selective NSAIDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2014</a>].  </li><li>A non-inferiority trial, the Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen or Naproxen (PRECISION) trial (n = 24,081) which assessed CV outcomes with long-term use concluded that celecoxib was non-inferior to naproxen and ibuprofen in terms of CV safety [<a class="bibliography-reference internal-reference" href="../../references/index.html">Nissen, 2016</a>].  </li><li>However, the design and study of the PRECISION trial has been questioned as [<a class="bibliography-reference internal-reference" href="../../references/index.html">Fitzgerald, 2016</a>]: <ul><li>68.8% of patients stopped taking the treatment drug and 27.4% discontinued follow‐up.</li><li>The study mostly included people with osteoarthritis at low CV risk.  </li><li>Due to the low number of events, the statistical power for non-inferiority was relaxed during the trial from 1.3 to 1.4.</li><li>The dose of celecoxib was restricted to just over 209 mg, while doses of ibuprofen and naproxen were allowed to be increased to attain efficacy — the mean daily doses of ibuprofen and naproxen were 2,045 mg and 852 mg respectively.</li><li>The trial did not take into account use of aspirin in people taking naproxen or ibuprofen, which may reduce the cardioprotective effect, while this interaction does not happen with celecoxib.</li></ul></li><li>The FDA concluded that the results of the PRECISION trial demonstrated that celecoxib, at the lowest approved dose of 100 mg twice daily, is non-inferior to ibuprofen 600–800 mg three times daily, or naproxen 375–500 mg twice daily on a composite cardiovascular endpoint consisting of CV death, nonfatal myocardial infarction, and nonfatal stroke [<a class="bibliography-reference internal-reference" href="../../references/index.html">FDA, 2018</a>]. <ul><li>Too few people received higher doses of celecoxib to evaluate the risk of CV events or the effect on blood pressure for doses greater than 100 mg twice daily, so this result cannot be extrapolated to higher doses (200 mg or 400 mg).</li></ul></li><li>A bayesian meta-analysis of individual patient data from four studies (involving 61,640 acute myocardial infarctions, across a population of 446,763 individuals) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Bally, 2017</a>], compared the risk of acute myocardial infarction in NSAID users (COX-2 inhibitors and traditional NSAIDs) with non-users, concluded that:   <ul><li>All NSAIDs, including naproxen, were associated with an increased risk of acute myocardial infarction (MI). </li><li>The risk of MI with celecoxib was comparable to that of traditional NSAIDS and was lower than for rofecoxib.</li><li>The risk was greatest during the first month of NSAID use and with higher doses.</li><li>The risk for longer than one month was no greater than for short term use.</li></ul></li><li>Nonsteroidal anti-inflammatory drugs (NSAIDs) should be prescribed at the lowest effective dose for the shortest possible duration [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>]. <ul><li>However, while use of NSAIDs in people with myocardial infarction and heart failure was thought to be risk-neutral in short treatment periods and in low doses, cumulating evidence suggests that there is no safe-treatment window.</li></ul></li></ul><!-- end field d29009a2-9e3d-46c0-b88a-582d256dede2 --><!-- end item 4f8b5d82-ab2d-4da4-a989-a28a757b20e3 --></div></section></section><section aria-labelledby="gastrointestinal-adverse-effects" class="ChapterBody-module--wrapper--2HCfk "><h3 id="gastrointestinal-adverse-effects">What are the risk factors for gastrointestinal (GI) adverse effects?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e4e222cd-1da8-4066-b4fa-1f03e28660e7 --><!-- begin field f583d6ce-2dc2-4bc9-aa6f-a93b00df8f1f --><ul><li>Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase-1 (COX-1) — this is thought to be responsible for gastrointestinal (GI) toxicity.<ul><li>COX-2 inhibitors (such as etoricoxib and celecoxib) selectively inhibit cyclo-oxygenase-2 and have a reduced risk for GI toxicity.</li></ul></li><li><strong>Risk factors for NSAID–induced gastrointestinal (GI) adverse events</strong><strong> include:</strong><ul><li>Aged over 65 years.</li><li>A high dose of an NSAID.</li><li>A history of gastroduodenal ulcer, GI bleeding, or gastroduodenal perforation.</li><li>Concomitant use of medications that are known to increase the likelihood of upper GI adverse events (for example, anticoagulants, corticosteroids, selective serotonin reuptake inhibitors [SSRIs]).</li><li>A serious comorbidity, such as cardiovascular disease, hepatic or renal impairment (including dehydration), diabetes, or hypertension. </li><li>Heavy smoking. </li><li>Excessive alcohol consumption. </li><li>Previous adverse reaction to NSAIDs.</li><li>Prolonged requirement for NSAIDs.</li></ul></li><li><strong>People are considered at: </strong><ul><li><strong>High risk </strong>if they have a history of previously complicated ulcer, or multiple (more than two) risk factors.</li><li><strong>Moderate risk</strong> if they have 1–2 risk factors.</li><li><strong>Low risk</strong> if they have no risk factors.</li></ul></li><li><strong>Additional risk factors for NSAID-induced GI adverse events include:</strong><ul><li>The type of NSAID used.</li><li>The presence of <em>Helicobacter pylori </em>infection.</li><li>For more information on risk factors, see the CKS topic on <a class="topic-reference external-reference" href="../../../dyspepsia-proven-gord/index.html">Dyspepsia - proven GORD</a>. </li></ul></li></ul><!-- end field f583d6ce-2dc2-4bc9-aa6f-a93b00df8f1f --><!-- end item e4e222cd-1da8-4066-b4fa-1f03e28660e7 --></div><section aria-labelledby="managing-risk" class="ChapterBody-module--wrapper--2HCfk "><h4 id="managing-risk">How should I manage the risk of GI adverse effects?</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cbc06f49-9d23-417d-aadf-a96c00b009a0 --><!-- begin field 0c5ee16c-5c22-48a6-bac1-a96c00b009d7 --><ul><li><strong>To prevent gastrointestinal (GI) adverse effects associated with the use of a nonsteroidal anti-inflammatory drug (NSAID):</strong><ul><li>Avoid prescribing more than one NSAID at a time.</li><li>Avoid concomitant use of an NSAID with low-dose aspirin (if possible) — if this is essential, monitor closely.</li><li>Prescribe the lowest dose of NSAID for the shortest period of time.</li><li>Use a short-acting NSAID (such as ibuprofen) in preference to a long-acting NSAID (such as naproxen). </li><li>Consider an alternative analgesic if appropriate.</li></ul></li><li><strong>For people: </strong><ul><li>With osteoarthritis and rheumatoid arthritis — co-prescribe a proton pump inhibitor (PPI) with an NSAID (see Table 1 for licensed doses of PPIs for gastroprotection).</li><li>Who are elderly — co-prescribe a PPI with an NSAID. </li><li>With low back pain, axial spondyloarthritis, psoriatic arthritis and other peripheral spondyloarthritides — consider gastroprotection when prescribing an NSAID. </li></ul></li><li><strong>For people at:</strong><ul><li><strong>High risk </strong>of<strong> </strong>GI adverse events — prescribe a COX-2 selective NSAID (for example, etoricoxib, or celecoxib) instead of a standard NSAID, and co-prescribe a PPI. </li><li><strong>Moderate risk </strong>of GI adverse events — prescribe a COX-2 inhibitor alone, or an NSAID plus a PPI. </li><li><strong>Low risk </strong>of GI events — prescribe a non-selective NSAID.</li></ul></li><li><strong>Managing GI adverse effects</strong><ul><li>The management of GI adverse effects in people using an NSAID depends on whether they have been investigated (for example, with endoscopy or a test for <em>H. pylori</em>) and whether 'alarm' symptoms are present. For full details, see the CKS topics on:<ul><li><a class="topic-reference external-reference" href="../../../dyspepsia-pregnancy-associated/index.html">Dyspepsia - pregnancy-associated</a></li><li><a class="topic-reference external-reference" href="../../../dyspepsia-proven-functional/index.html">Dyspepsia - proven functional</a></li><li><a class="topic-reference external-reference" href="../../../dyspepsia-proven-peptic-ulcer/index.html">Dyspepsia - proven peptic ulcer</a></li><li><a class="topic-reference external-reference" href="../../../dyspepsia-unidentified-cause/index.html">Dyspepsia - unidentified cause</a></li></ul></li></ul></li><li>For detailed information on the use of low-dose aspirin, including advice on how to minimize the risk of GI adverse events, see the CKS topic on <a class="topic-reference external-reference" href="../../../antiplatelet-treatment/index.html">Antiplatelet treatment</a>.</li></ul><!-- end field 0c5ee16c-5c22-48a6-bac1-a96c00b009d7 --><!-- end item cbc06f49-9d23-417d-aadf-a96c00b009a0 --></div></section><section aria-labelledby="proton-pump-inhibitor-doses-for-gastroprotection" class="ChapterBody-module--wrapper--2HCfk "><h4 id="proton-pump-inhibitor-doses-for-gastroprotection">Licensed doses of proton pump inhibitors used for gastroprotection for people who require continued NSAID treatment</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item e35bf65b-6afe-4c4e-9bd4-142cc460b8bd --><!-- begin field 3ab7dfe7-e62b-4c46-b60b-13ea4669f45b --><p><strong>Table 1. </strong>Licensed doses of proton pump inhibitors used for gastroprotection for people who require continued NSAID treatment.</p><table><thead><tr><th colspan="1">Proton Pump Inhibitor</th><th colspan="1">Dose for NSAID prophylaxis</th></tr></thead><tbody><tr><td colspan="1">Lansoprazole</td><td colspan="1">15–30 mg once daily</td></tr><tr><td colspan="1">Omeprazole</td><td colspan="1">20 mg once daily</td></tr><tr><td colspan="1">Esomeprazole</td><td colspan="1">20 mg once daily</td></tr><tr><td colspan="1">Pantoprazole</td><td colspan="1">20 mg once daily</td></tr><tr><td colspan="2"><strong>Information from: </strong>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>]</td></tr></tbody></table><!-- end field 3ab7dfe7-e62b-4c46-b60b-13ea4669f45b --><!-- end item e35bf65b-6afe-4c4e-9bd4-142cc460b8bd --></div></section><section aria-labelledby="basis-for-recommendation-642" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-642">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 6426eeb2-b7fd-4b59-9c4c-270b654baf01 --><!-- begin field c3ea355e-b372-4787-893e-12d0390a3218 --><p>These recommendations are based on the American College of Gastroenterology (ACG) guideline <em>Guidelines for Prevention of NSAID-Related Ulcer Complications </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanza, 2009</a>], the National Institute for Health and Care Excellence (NICE) guidelines <em>Osteoarthritis: care and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014a</a>], <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014b</a>], <em>Low back pain and sciatica in over 16s: assessment and management </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2016</a>], <em>Rheumatoid arthritis in adults: management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018b</a>], the European Society of Cardiology (ESC) review and position paper <em>Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>], the British Pain Society (BPS) <em>Guidance on the management of pain in older people</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BPS, 2013</a>], systematic reviews <em>Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Castellsague, 2012</a>], and <em>C</em><em>omparative effectiveness and safety of strategies for preventing NSAID-associated gastrointestinal toxicity </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Yuan, 2016</a>], expert opinion in a medical textbook <em>Medical Pharmacology at a glance</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Neal, 2015</a>], expert opinion in narrative reviews <em>Non-steroidal anti-inflammatory drugs (NSAIDs) </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">O&#39;Day, 2013</a>], and <em>Non-steroidal anti-inflammatory drugs (NSAIDs): making safer treatment choices </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BPJ, 2013</a>], a consensus report <em>Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Malfertheiner, 2017</a>], and the British National Formulary [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>].   </p><h5>Risk stratification and NSAID treatment choice</h5><ul><li>NICE considers that people with a previous peptic ulcer are at high risk of GI adverse effects and should be prescribed a COX-2 inhibitor plus a PPI, or if a standard NSAID is preferred, a PPI should be co-prescribed [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014b</a>].</li><li>The ACG considers that people with a previous uncomplicated ulcer (and no other risk factors) are at moderate risk, while people with a previous complicated ulcer are at high risk of GI adverse events [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lanza, 2009</a>]. </li><li>CKS recommends using clinical judgement to determine the individual risk of GI adverse effects for people starting NSAIDs and when deciding if gastroprotection is required. </li></ul><h5>Managing GI risk </h5><ul><li>Coxibs are associated with a reduction in the risk of GI symptoms and complications compared with standard NSAIDs, but they do not eliminate the risk of GI adverse effects [<a class="bibliography-reference internal-reference" href="../../references/index.html">Rostom et al, 2007</a>]. <ul><li>Selectivity for COX-2 represents a continuum, and COX-2 inhibitors can therefore be ranked based on their relative COX-2 vs COX-1 selectivity, with etoricoxib more selective than celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schmidt, 2016</a>]. </li></ul></li><li>Proton pump inhibitors (PPIs) are well tolerated and effective at reducing the GI risks associated with NSAIDs and reduce the risks to a similar level as using a coxib alone [<a class="bibliography-reference internal-reference" href="../../references/index.html">Chan et al, 2002</a>]. </li><li>The combination of selective COX-2 inhibitors plus PPIs provides the best gastrointestinal protection, followed by selective COX-2 inhibitors alone, and thirdly by nonselective NSAIDs plus PPIs [<a class="bibliography-reference internal-reference" href="../../references/index.html">Yuan, 2016</a>]. </li><li>Options for gastroprotective drugs to prescribe with standard NSAIDs also include misoprostol or a histamine<sub>2</sub>–receptor antagonist, but a PPI is the preferred choice [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>]. </li></ul><!-- end field c3ea355e-b372-4787-893e-12d0390a3218 --><!-- end item 6426eeb2-b7fd-4b59-9c4c-270b654baf01 --></div></section></section><section aria-labelledby="drug-interactions" class="ChapterBody-module--wrapper--2HCfk "><h3 id="drug-interactions">Drug interactions</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item be256121-4626-4ef1-8ef0-a01943b023e0 --><!-- begin field c62d73dd-5a36-4642-affd-f9252611b8d3 --><ul><li><strong>Alendronate</strong> — concurrent use with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of upper gastrointestinal (GI) adverse effects. Monitor for signs of GI irritation.</li><li><strong>Angiotensin-converting enzyme (ACE) inhibitors or an angiotensin-II receptor antagonists (AIIRAs) </strong>— concurrent use with NSAIDs may increase blood pressure, the risk of renal impairment and rarely hypokalaemia. Monitor blood pressure if an NSAID is started, and consider monitoring urea and electrolytes. Consider intermittent use of NSAIDs as a possible cause if erratic blood pressure control occurs.</li><li><strong>Anticoagulants </strong>(for example, warfarin, dabigatran) — all NSAIDs can cause GI irritation and reduce platelet aggregation, which can worsen any bleeding event. Avoid concomitant use if possible. <ul><li>If concurrent use is necessary be aware of the potential risks of bleeding. Consider giving gastroprotection (such as a proton pump inhibitor [PPI]).</li></ul></li><li><strong>Antidepressants </strong>— increased risk of upper GI bleeding when some antidepressants (selective serotonin reuptake inhibitors, and serotonin noradrenaline reuptake inhibitors) and an NSAID are taken concomitantly. If an NSAID is considered necessary, weigh the risks and benefits of treatment and consider prescribing gastroprotection.</li><li><strong>Antiplatelets (low dose aspirin, clopidogrel) </strong>— NSAIDs may antagonize the antiplatelet effects of aspirin, and increase the risk of GI bleeds when taken concurrently with other antiplatelets. If concomitant use is unavoidable consider prescribing gastroprotection with a PPI.</li><li><strong>Beta blockers</strong> — NSAIDs may reduce the efficacy of beta blockers given for heart failure. Consider monitoring blood pressure if an NSAID is started or stopped.<ul><li><strong>Note:</strong> NSAIDs should generally be avoided in people with heart failure.</li></ul></li><li><strong>Corticosteroids </strong>— the incidence and/or severity of ulceration associated with NSAIDs, and the possibility of GI bleeding may be increased. Consider giving gastroprotection.</li><li><strong>Ciclosporin </strong>— NSAIDs may reduce renal function, and lead to increased ciclosporin levels. If concurrent is necessary, monitor renal function and consider reducing the dose of the NSAID. </li><li><strong>Fluconazole, voriconazole</strong> — the peak plasma level of some NSAIDs (for example, ibuprofen) may be increased. Monitor for NSAID adverse effects (for example, dyspepsia, nausea, dizziness). Consider using the lowest NSAID dose and titrate accordingly.</li><li><strong>Lithium </strong>— NSAIDs can reduce lithium excretion, and increase the risk of lithium toxicity. Avoid concomitant use especially if risk factors for lithium toxicity (such as advanced age or renal impairment) are present, unless lithium levels can be closely monitored, and the dose adjusted accordingly. Advise people to report lithium adverse effects (tremor, dysarthria, ataxia, confusion).</li><li><strong>Loop diuretics (for example, furosemide) </strong>— NSAIDs may reduce the antihypertensive effects of loop diuretics and exacerbate congestive heart failure. Consider an alternative non-NSAID analgesic, but if concurrent use is essential, monitor the diuretic effects, renal function and electrolytes closely, and increase the dose of the loop diuretic if required. </li><li><strong>Methotrexate </strong>— NSAIDs may reduce the excretion of methotrexate and increase the risk of methotrexate toxicity. Advise people to report symptoms such as sore throat, dyspnoea or cough.<ul><li>If high-dose methotrexate is given with an NSAID, monitor methotrexate levels and increase routine methotrexate monitoring (full blood count, liver function tests).</li></ul></li><li><strong>Nicorandil </strong>— there may be an increased risk of GI ulceration, perforation or haemorrhage if taken concurrently with an NSAIDs. Monitor for GI adverse effects.</li><li><strong>Potassium-sparing diuretics (for example, spironolactone) </strong>— several cases of acute renal impairment have been reported with concurrent use with NSAIDs. Avoid concurrent use.</li><li><strong>Probenecid </strong>— probenecid reduces excretion of NSAIDs. Avoid concurrent use.<ul><li>If concurrent use is unavoidable, use a lower dose of NSAID. Ketorolac is specifically contraindicated in people taking probenecid.</li></ul></li><li><strong>Quinolones (for example, ciprofloxacin) </strong>— possible increased risk of convulsions if taken concurrently. This is rare, therefore in most cases, the concomitant use of a quinolone and an NSAID is acceptable. However concurrent use should be avoided in people with epilepsy or people who are predisposed to convulsions.</li><li><strong>Thiazide-type diuretics (for example, bendroflumethiazide) </strong>— some NSAIDS (for example, indometacin) may reduce the antihypertensive effect of thiazides.<ul><li>If concurrent use is indicated monitor blood pressure regularly and increase the thiazide dose as necessary.</li></ul></li><li><strong>Zidovudine</strong> — the risk of haematological toxicity and risk of bleeding may be increased if given concurrently with NSAIDs.</li><li><strong>Note: </strong>combined treatment with an NSAID, plus an ACE inhibitor or AIIRA and a diuretic (the so called 'triple whammy') significantly increases the risk of acute kidney injury (AKI) and should be avoided if possible. For more information on people most at risk of AKI and how to manage them, see the CKS topic on <a class="topic-reference external-reference" href="../../../acute-kidney-injury/index.html">Acute kidney injury</a>.  </li></ul><!-- end field c62d73dd-5a36-4642-affd-f9252611b8d3 --><!-- end item be256121-4626-4ef1-8ef0-a01943b023e0 --></div><section aria-labelledby="basis-for-recommendation-ed3" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-ed3">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item ed3f036a-f570-4c22-b533-de8ce2dcb396 --><!-- begin field 5c9cbfda-799a-42d1-a4b0-482844a71249 --><p>These recommendations are based on the medical textbook <em>Stockley's drug interactions </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Preston, 2016</a>], the<em> British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>], expert opinion in a narrative review <em>Non-steroidal anti-inflammatory drugs (NSAIDs): making safer treatment choices </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">BPJ, 2013</a>], <em> </em>the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>], and a retrospective cohort study <em>Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lapi, 2013</a>]. </p><h5>Triple whammy interaction </h5><ul><li>Triple therapy with a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor or angiotensin-II receptor antagonist (AIIRAs) and diuretic is associated with an increased risk of acute kidney injury [<a class="bibliography-reference internal-reference" href="../../references/index.html">BPJ, 2013</a>].   </li><li>A nested case-control study of people using antihypertensive drugs (n = 487,372) which identified 2215 cases of acute kidney injury found that current use of triple therapy (ACE inhibitor/AIIRAs, a diuretic and an NSAID) was associated with an increased rate of acute kidney injury (Rate Ratio 1.31, 95% CI 1.12–1.53) compared to double therapy (diuretic plus ACE inhibitor/AIIRA). The greatest risk was observed in the first 30 days of use (Rate Ratio 1.82, 95% CI 1.35-2.46) [<a class="bibliography-reference internal-reference" href="../../references/index.html">Lapi, 2013</a>]. </li></ul><!-- end field 5c9cbfda-799a-42d1-a4b0-482844a71249 --><!-- end item ed3f036a-f570-4c22-b533-de8ce2dcb396 --></div></section></section><section aria-labelledby="monitoring" class="ChapterBody-module--wrapper--2HCfk "><h3 id="monitoring">Monitoring</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item cfddcb34-0b63-4e1d-abff-09cf0b508b6b --><!-- begin field d5c247d0-ef3e-4242-a51b-2b25b7902ad7 --><ul><li><strong>Review the appropriateness of non-steroidal anti-inflammatory drug (NSAID) prescribing widely and on a routine basis</strong>, especially in people who are at higher risk of gastrointestinal, renal and cardiovascular morbidity and mortality (for example, older people). <ul><li>Consider the risks and the response to treatment, and use clinical judgement to decide what must be monitored and how frequently.</li><li>Enquire about, and manage, <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a>.</li></ul></li><li><strong>Monitor blood pressure in the elderly and people:</strong><ul><li>Taking COX-2 inhibitors.<ul><li>Before starting treatment. </li><li>Two weeks after treatment for etoricoxib. </li><li>Periodically during treatment.</li></ul></li><li>With hypertension — for example, 1–4 weeks after starting long-term treatment, or increasing the dose of the NSAID. </li></ul></li><li><strong>Monitor renal function at least annually. </strong><ul><li>For people with renal impairment — monitor renal function 1–2 weeks after starting or increasing the dose of the NSAID, and then regularly thereafter. </li></ul></li><li><strong>Monitor liver function</strong> in people:<ul><li>With hepatic impairment.</li><li>On long-term NSAID therapy.</li></ul></li><li><strong>Monitor haemoglobin levels</strong> in people at high risk of gastrointestinal adverse effects 1–4 weeks after NSAID treatment has started.</li><li><ul></ul><strong>Consider monitoring blood pressure, renal function, and features of heart failure </strong>1–2 weeks after starting or increasing the dose of the NSAID, and then regularly thereafter, in the elderly and people with: <ul><li>Ischaemic heart disease.</li><li>Risk factors for cardiovascular disease.</li><li>Cerebrovascular disease. </li><li>Peripheral vascular disease.</li><li>Heart failure.</li></ul></li><li>Also consider monitoring renal function in people who are taking additional drugs that can affect renal function (for example, ACE inhibitors, angiotensin-II receptor antagonists, or diuretics).</li><li>For more specific advice check the drug's <a data-hyperlink-id="8c583452-31be-4256-baba-a93100ad9e2c" href="http://www.medicines.org.uk/">summary of product characteristics</a> (SPC).</li></ul><!-- end field d5c247d0-ef3e-4242-a51b-2b25b7902ad7 --><!-- end item cfddcb34-0b63-4e1d-abff-09cf0b508b6b --></div><section aria-labelledby="basis-for-recommendation-a0a" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-a0a">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item a0a86100-fee9-46a5-8e1c-0d64733998d5 --><!-- begin field d931550c-4ae1-4f4f-91c7-d954c74e593f --><p>These recommendations are pragmatic and largely based on the National Institute for Health and Care Excellence (NICE) key therapeutic topic <em>Nonsteroidal anti-inflammatory drugs </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2018a</a>], the guideline <em>Chronic kidney disease in adults: assessment and management</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2014c</a>], expert opinion in narrative reviews <em>Non-steroidal anti-inflammatory drugs (NSAIDs): making safer treatment choices</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BPJ, 2013</a>], and <em>Non-steroidal anti-inflammatory drugs (NSAIDs)</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">O&#39;Day, 2013</a>], the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>], and the <em>British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>].</p><ul><li>Fluid retention and oedema are associated with NSAIDs therapy, so particular caution is required in people with impaired cardiac or renal function, history of hypertension, the elderly, and people receiving concomitant treatment with diuretics or medicinal products that can significantly impact renal function [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>]. </li><li>The suggested monitoring intervals in people starting nonsteroidal anti-inflammatory drugs (NSAIDS) who also have heart failure, hypertension, or renal impairment, are extrapolated from the monitoring advice for people starting ACE inhibitors. See the CKS topics on <a class="topic-reference external-reference" href="../../../chronic-kidney-disease/index.html">Chronic kidney disease</a>, <a class="topic-reference external-reference" href="../../../hypertension-not-diabetic/index.html">Hypertension - not diabetic</a>, and <a class="topic-reference external-reference" href="../../../heart-failure-chronic/index.html">Heart failure - chronic</a> for further information.</li></ul><!-- end field d931550c-4ae1-4f4f-91c7-d954c74e593f --><!-- end item a0a86100-fee9-46a5-8e1c-0d64733998d5 --></div></section></section><section aria-labelledby="conception" class="ChapterBody-module--wrapper--2HCfk "><h3 id="conception">Conception</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item f102aee1-3191-4428-b047-382fc530f7c4 --><!-- begin field b697bd95-bc37-469a-bcfe-9c781adbc6bb --><ul><li><strong>Avoid nonsteroidal anti-inflammatory drugs (NSAIDs) during conception.</strong></li><li>Paracetamol is the analgesic and/or antipyretic of choice during conception.</li></ul><!-- end field b697bd95-bc37-469a-bcfe-9c781adbc6bb --><!-- end item f102aee1-3191-4428-b047-382fc530f7c4 --></div><section aria-labelledby="basis-for-recommendation-860" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-860">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 860dc8fb-0fbd-4afc-adf5-d831c73e54ac --><!-- begin field 180511b8-463e-4737-b9f2-69bdedb5513c --><p>These recommendations are based on the<em> British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>], the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>], expert opinion in a medical textbook <em>Drugs during pregnancy and Lactation: treatment options and risk assessment</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>], and a prospective cohort study<em> Exposure to non-steroidal anti-inflammatory drugs during pregnancy and risk of miscarriage: population based cohort study </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">Li, 2003</a>]. </p><ul><li>Long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>]. </li><li>NSAID use around conception has been associated with an increased risk of miscarriage. In a prospectively conducted study which recruited more than 1000 women with a positive pregnancy test, 53 (5%) of whom reported NSAID use, there was a nearly 2-fold risk for miscarriage in those who had used naproxen or ibuprofen compared to non-users [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>; <a class="bibliography-reference internal-reference" href="../../references/index.html">Li, 2003</a>].<ul><li>Suppression of prostaglandin synthesis could lead to abnormal implantation resulting in miscarriage. However, conclusive evidence on causal association is lacking [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>]. </li><li>The associated risk was particularly high when NSAIDs were used around the time of conception, and the risk was also higher when NSAIDs were used for longer than a week [<a class="bibliography-reference internal-reference" href="../../references/index.html">Li, 2003</a>]. </li><li>Use of paracetamol during pregnancy was not associated with risk of miscarriage regardless of the timing or duration of use [<a class="bibliography-reference internal-reference" href="../../references/index.html">Li, 2003</a>]. </li></ul></li><li>Paracetamol is the analgesic and antipyretic of first choice during pregnancy, and can be used in any trimester when indicated [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>]. </li></ul><!-- end field 180511b8-463e-4737-b9f2-69bdedb5513c --><!-- end item 860dc8fb-0fbd-4afc-adf5-d831c73e54ac --></div></section></section><section aria-labelledby="pregnancy" class="ChapterBody-module--wrapper--2HCfk "><h3 id="pregnancy">Pregnancy</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 0477a1bc-6785-4eb2-80cf-b0ed4eacab45 --><!-- begin field 30fd0310-eb8c-45fc-95c4-1565c3452aed --><ul><li>Paracetamol is the analgesic and/or antipyretic of choice during pregnancy.</li><li>However, if during the first or second trimester paracetamol is ineffective and an NSAID is clinically indicated:<ul><li>Ibuprofen is the preferred NSAID — however, it should only be used before 30 weeks of pregnancy.<ul><li>COX-2 inhibitors are contraindicated.</li></ul></li><li>As with all people who are prescribed an NSAID, use the lowest effective dose for the shortest duration possible.</li><li>If regular use is clinically indicated, such as in a woman with rheumatoid arthritis, seek specialist advice.</li></ul></li><li>NSAIDs must not be used from 30 weeks of pregnancy onwards without specialist advice and regular fetal monitoring.<ul><li>Use after 30 weeks of pregnancy is associated with premature closure of the ductus arteriosus.</li></ul></li><li>For more information, contact the UK Teratology Information Service (UKTIS) on 0844 892 0909.</li></ul><!-- end field 30fd0310-eb8c-45fc-95c4-1565c3452aed --><!-- end item 0477a1bc-6785-4eb2-80cf-b0ed4eacab45 --></div><section aria-labelledby="basis-for-recommendation-510" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-510">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 51026ba0-4e43-419b-b952-f62b2250c05f --><!-- begin field d787ec78-4e6c-4b45-806e-ff2cf5796ae5 --><p>These recommendations are based on the UK Teratology Information Service (UKTIS) articles <em>Use of nonsteroidal anti-inflammatory drugs (NSAIDs) in pregnancy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2014</a>], <em>Therapeutic use of paracetamol in pregnancy</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2017</a>], expert opinion in a medical textbook <em>Drugs during pregnancy and Lactation: treatment options and risk assessment</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>], the<em> British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>], and <em>​​​</em>the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>].</p><h5>Use of NSAIDs in pregnancy</h5><ul><li>NSAIDs should only be used in the first and second trimesters if clearly necessary [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>].<ul><li>All NSAIDs should be avoided in the third trimester [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2014</a>].</li><li>Exposure to NSAIDs after 30 weeks' gestation has been associated with an increased risk of premature closure of the ductus arteriosus and oligohydramnios [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2014</a>].</li><li>Repeated use of NSAIDs should be avoided after the twenty-eighth week of pregnancy as inhibition of prostaglandin synthesis after 28 weeks' gestation may lead to premature closure of the ductus arteriosus and renal impairment in the fetus [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>].</li></ul></li><li>Ibuprofen is the analgesic of choice after paracetamol, and the anti-inflammatory agent of first choice until 28 weeks' gestation. Use of diclofenac is also possible [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>].</li><li>COX-2 inhibitors are contraindicated at any stage of pregnancy [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>].</li></ul><h5>Use of paracetamol during pregnancy</h5><ul><li>Paracetamol is the analgesic/antipyretic of first choice in pregnancy and can be used in any trimester when indicated [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>].</li><li>Paracetamol use in pregnancy has been associated with an increased incidence of [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2017</a>]:<ul><li>Cryptorchidism in male offspring following paracetamol use during pregnancy, although findings are conflicting.</li><li>Wheezing or childhood asthma with frequent paracetamol use during late pregnancy (20–32 weeks).</li><li>Poorer gross motor development, communication skills, externalising and internalising behaviours, and to have higher activity levels in children exposed to paracetamol in utero.</li><li>Behaviour subtypes that may be indicative of ADHD.</li><li>Symptoms of autism spectrum disorder (ASD) in boys (but not girls), and an increased risk of ASD with hyperkinetic symptoms in children but no increased risk of ASD without hyperkinetic symptoms.</li></ul></li><li>However, a causal association with an increased risk of any adverse fetal outcome following therapeutic paracetamol use (500–1000mg up to four times a day, with a maximum dose of 4g within a 24 hour period) in pregnancy remains to be proven [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKTIS, 2017</a>].</li></ul><!-- end field d787ec78-4e6c-4b45-806e-ff2cf5796ae5 --><!-- end item 51026ba0-4e43-419b-b952-f62b2250c05f --></div></section></section><section aria-labelledby="breastfeeding" class="ChapterBody-module--wrapper--2HCfk "><h3 id="breastfeeding">Breastfeeding</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item d424e5cb-0260-4e49-af33-21a26cc24a53 --><!-- begin field 9303049a-2fa5-4a4c-8fdd-78989b4591cd --><ul><li>Paracetamol is the drug of choice for women who are breastfeeding. Seek expert advice if the:<ul><li>Infant is pre-term, or low birthweight.</li><li>Absorption, distribution, metabolism, or excretion of paracetamol may be affected by an underlying medical condition.</li></ul></li><li>If a nonsteroidal anti-inflammatory drug (NSAID) is clinically indicated:<ul><li>Ibuprofen is preferred.</li><li>Use the lowest effective dose for the shortest time possible.</li></ul></li><li>If a COX-2 inhibitor is clinically indicated:<ul><li>Celecoxib is preferred.</li></ul></li><li>If a non-preferred NSAID is required, monitor the infant for gastrointestinal adverse effects, and avoid repeated use of drugs with a long half-life (for example, naproxen) where possible, due to the potential risk of accumulation in the infant.<ul><li>Single doses of non-preferred NSAIDs may be used if required without the need for monitoring. </li></ul></li></ul><!-- end field 9303049a-2fa5-4a4c-8fdd-78989b4591cd --><!-- end item d424e5cb-0260-4e49-af33-21a26cc24a53 --></div><section aria-labelledby="basis-for-recommendation-dd5" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-dd5">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item dd5135ac-70f7-487c-815c-d3e51df0b5a5 --><!-- begin field bfe8676e-4a39-46d7-b20d-3982c3d034ab --><p>These recommendations are based on expert opinion in a medical textbook <em>Drugs during pregnancy and Lactation: treatment options and risk assessment</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">Schaefer, 2015</a>], the UK Medicines Information (UKMI) document <em>Can breastfeeding mothers take paracetamol?</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">UKMi, 2015</a>], the Specialist Pharmacy Service (SPS) article <em>Safety in lactation: nonsteroidal anti-inflammatory drugs</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">SPS, 2016</a>], the<em> British National Formulary</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">BNF 75, 2018</a>], ​​​and the manufacturers' Summaries of Product Characteristics for Diclomax retard [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018a</a>], ibuprofen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018b</a>], naproxen [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018c</a>], celecoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018d</a>], and etoricoxib [<a class="bibliography-reference internal-reference" href="../../references/index.html">ABPI, 2018e</a>].</p><!-- end field bfe8676e-4a39-46d7-b20d-3982c3d034ab --><!-- end item dd5135ac-70f7-487c-815c-d3e51df0b5a5 --></div></section></section><section aria-labelledby="advice" class="ChapterBody-module--wrapper--2HCfk "><h3 id="advice">What advice should I give someone when prescribing an NSAIDs?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 43b984de-f88e-405b-bd00-e0ad731dfa1d --><!-- begin field d930f71c-47a9-4c41-92fa-f67b167f4c27 --><ul><li>Advise the person about the <a class="topic-reference internal-reference" href="index.html#adverse-effects">adverse effects</a> associated with NSAIDs including the <a class="topic-reference internal-reference" href="index.html#cardiovascular-renal-adverse-effects">cardiovascular and renal</a> and <a class="topic-reference internal-reference" href="index.html#gastrointestinal-adverse-effects">gastrointestinal</a> (GI) adverse effects. </li><li>Explain that adverse effects may be minimized by:<ul><li>Using an alternative treatment to an oral NSAID (for example paracetamol, or a topical NSAID if appropriate).</li><li>Using an NSAID at the lowest effective dose and for no longer than is necessary.</li><li>Taking an NSAID with or after food.</li><li>Taking a proton pump inhibitor if they have an increased risk of GI adverse effects.</li></ul></li><li>Explain that they may need close <a class="topic-reference internal-reference" href="index.html#monitoring">monitoring</a> to determine the response to treatment and manage any adverse effects.</li><li>Advise them to read the patient information leaflet that comes with their medicine.</li><li>Provide the person with a <a data-hyperlink-id="45ff8869-d13d-4110-a18c-a93f00a97d98" href="https://ihub.scot/spsp/primary-care/medicine-sick-day-rules-card/">Medicine Sick Day Rules Card</a>, and explain that they should: <ul><li>Stop the NSAID (and any of the other medicines mentioned on the card) when they are unwell with vomiting or diarrhoea (unless minor), or fever, sweats and shaking (unless minor).</li><li>Restart when they are well (after 24–48 hours of normal eating and drinking).</li></ul></li></ul><!-- end field d930f71c-47a9-4c41-92fa-f67b167f4c27 --><!-- end item 43b984de-f88e-405b-bd00-e0ad731dfa1d --></div><section aria-labelledby="basis-for-recommendation-9e4" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-9e4">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 9e4ca030-36c4-490a-a330-dc40156ddd62 --><!-- begin field 13c66c93-9828-4661-b7d9-2a0f193bc56d --><p>These recommendations are pragmatic and what CKS consider good clinical practice. </p><!-- end field 13c66c93-9828-4661-b7d9-2a0f193bc56d --><!-- end item 9e4ca030-36c4-490a-a330-dc40156ddd62 --></div></section></section><section aria-labelledby="covid-19" class="ChapterBody-module--wrapper--2HCfk "><h3 id="covid-19">How should my management vary when considering the possibility of COVID-19?</h3><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item 79fe5903-ed0a-44cc-ac48-ab9e00dea405 --><!-- begin field 904eb731-acb2-4161-bdb8-ab9e00dea42f --><ul><li>NSAIDs are commonly used over the counter and prescribed by clinicians for people suffering symptoms resulting from acute respiratory infections (ARI). </li><li>The advice on prescribing NSAIDs to someone with proven or suspected COVID-19 infection is that this should be done with caution. For each person, the following should be taken into account: <ul><li>Comorbidities and medical history.</li><li>Risks in each person.</li><li>Contraindications.</li><li>Interactions.</li><li>Monitoring requirements.</li></ul></li><li>If NSAIDs are prescribed, then this should be at the lowest dose and for the shortest period. </li><li>The need for continued NSAIDs should be reviewed using clinical judgement. </li><li>Naproxen and low-dose ibuprofen (up to 1200 mg per day) are considered first-choice options. </li><li>For people who are taking NSAIDs long term for other indications, the advice is that there no need for them to stop their treatment.</li></ul><!-- end field 904eb731-acb2-4161-bdb8-ab9e00dea42f --><!-- end item 79fe5903-ed0a-44cc-ac48-ab9e00dea405 --></div><section aria-labelledby="basis-for-recommendation-de6" class="ChapterBody-module--wrapper--2HCfk "><h4 id="basis-for-recommendation-de6">Basis for recommendation</h4><div class="ChapterBody-module--body--2n0CK" aria-hidden="false"><!-- begin item de657896-3d5c-41be-971e-ab9e00dea431 --><!-- begin field 82f697fb-5132-4c6d-bac5-ab9e00dea431 --><p>The recommendation to prescribe with caution is based on NICE <em>COVID-19 rapid evidence summary: acute use of non-steroidal anti-inflammatory drugs (NSAIDs) for people with or at risk of COVID-19</em> [<a class="bibliography-reference internal-reference" href="../../references/index.html">NICE, 2020</a>] and the Centre for Evidence Based Medicine (CEBM) review on <em>NSAIDs in acute respiratory infection (not including COVID-19) </em>[<a class="bibliography-reference internal-reference" href="../../references/index.html">CEBM, 2020</a>] that concluded that NSAIDs ‘do not significantly reduce total symptoms or duration of respiratory infections’. As a result of several publications, which suggest the possibility of poorer outcomes for people with ARI who are also prescribed NSAIDs, the CEBM, therefore, advises that there is a need for caution when using NSAIDs for acute respiratory infections.</p><p>The basis for considering individual risk factors for adverse effects should be taken into account, including any contraindications, drug interactions, pre-existing conditions and medical history, and any monitoring requirements is based on the CEBM review and NICE guidance.</p><p>The CEBM also advise that clinicians prescribe the lowest effective dose of an NSAID for the shortest period required to control symptoms and the need for long-term treatment should be reviewed periodically.</p><p>The European Medicines Agency (EMA) [<a class="bibliography-reference internal-reference" href="../../references/index.html">EMA, 2020</a>] advises that, when starting treatment for fever or pain in COVID-19, patients and healthcare professionals should consider all available treatment options, including paracetamol and NSAIDs.</p><p>The Medicines and Healthcare products Regulatory Authority (MHRA) advises that naproxen and low-dose ibuprofen (up to 1200 mg per day) are considered to have the most favourable thrombotic cardiovascular safety profiles of all NSAIDs [<a class="bibliography-reference internal-reference" href="../../references/index.html">MHRA, 2020</a>].</p><p>The EMA and NICE also advise that there is currently no reason for patients taking ibuprofen to interrupt their treatment. They stress that this is particularly important for patients taking ibuprofen or other NSAIDs for chronic diseases.</p><!-- end field 82f697fb-5132-4c6d-bac5-ab9e00dea431 --><!-- end item de657896-3d5c-41be-971e-ab9e00dea431 --></div></section></section></section></div></div></div><div class="BackToTop-module--wrapper--2Z0EU"><nav aria-labelledby="back-to-top-link" class="BackToTop-module--nav--1DPZ6"><a class="BackToTop-module--anchor--1Nia6" id="back-to-top-link" href="index.html#content-start"><div class="container"><svg width="1em" height="1em" viewBox="0 0 512 512" fill="none" class="icon" aria-hidden="true" focusable="false"><path d="M478.152 338.576c0 10.091-3.525 18.661-10.576 25.712l-21.424 21.424c-7.243 7.243-15.909 10.864-26 10.864-10.283 0-18.853-3.621-25.712-10.864L255.576 247.136 116.712 385.712c-6.859 7.243-15.429 10.864-25.712 10.864s-18.853-3.621-25.712-10.864l-21.424-21.424C36.621 357.429 33 348.859 33 338.576c0-10.091 3.621-18.757 10.864-26l186-186c7.051-7.051 15.621-10.576 25.712-10.576 9.909 0 18.576 3.525 26 10.576l185.712 186c7.243 7.243 10.864 15.909 10.864 26z" fill="currentColor"></path></svg> Back to top</div></a></nav></div></main><footer class="Footer-module--footer--2QrGZ"><div class="Footer-module--container--1iuoB"><a href="https://www.nice.org.uk/" class="Footer-module--logo--3DGKv" aria-label="Go to NICE home page"></a><nav class="Services-module--wrapper--2qOoE" aria-label="Our services"><ul class="Services-module--list--3SZQu"><li><a href="https://pathways.nice.org.uk/" class="Services-module--link--2y_1q">NICE Pathways</a></li><li><a href="https://www.nice.org.uk/guidance" class="Services-module--link--2y_1q">NICE guidance</a></li><li><a href="https://www.nice.org.uk/standards-and-indicators" class="Services-module--link--2y_1q">Standards and indicators</a></li><li><a href="https://www.evidence.nhs.uk/" class="Services-module--link--2y_1q">Evidence search</a></li><li><a href="https://bnf.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary">BNF<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary</span></a></li><li><a href="https://bnfc.nice.org.uk/" class="Services-module--link--2y_1q"><abbr title="British National Formulary for Children">BNFC<!-- --> <span class="Services-module--visuallyHidden--t9mfm">British National Formulary for Children</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">British National Formulary for Children</span></a></li><li><a href="../../../../index.html" aria-current="true" class="Services-module--link--2y_1q"><abbr title="Clinical Knowledge Summaries">CKS<!-- --> <span class="Services-module--visuallyHidden--t9mfm">Clinical Knowledge Summaries</span></abbr><span aria-hidden="true" class="Services-module--tooltip--pg3nW">Clinical Knowledge Summaries</span></a></li><li><a href="https://www.nice.org.uk/about/what-we-do/evidence-services/journals-and-databases" class="Services-module--link--2y_1q">Journals and databases</a></li></ul></nav><nav class="Pages-module--wrapper--30REl"><ul class="Pages-module--list--vvSk4"><li><a href="https://www.nice.org.uk/about">About NICE</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/into-practice">Into practice</a></li><li><a href="https://www.nice.org.uk/get-involved">Get involved with NICE</a></li><li><a href="https://www.nice.org.uk/get-involved/jobs">Jobs</a></li><li><a href="https://www.nice.org.uk/news">News</a></li><li><a href="https://www.nice.org.uk/news/nice-newsletters-and-alerts">Newsletters and alerts</a></li><li><a href="https://www.nice.org.uk/get-involved/contact-us">Contact us</a></li><li><a href="https://www.nice.org.uk/leave-feedback">Leave feedback</a></li><li><a href="https://www.nice.org.uk/re-using-our-content">Reusing our content</a></li><li><a href="https://www.nice.org.uk/re-using-our-content/uk-open-content-licence">NICE UK Open Content Licence</a></li><li><a href="https://www.nice.org.uk/about/what-we-do/nice-syndication-api">Syndicate our content</a></li></ul></nav><div class="Social-module--wrapper--2nKsd"><ul class="Social-module--list--E5R5J" aria-label="NICE on social media"><li><a href="https://en-gb.facebook.com/NationalInstituteforHealthandCareExcellence/">Facebook</a></li><li><a href="https://twitter.com/NICEcomms">Twitter</a></li><li><a href="https://www.youtube.com/user/NICEmedia">YouTube</a></li><li><a href="https://www.instagram.com/nicecomms/">Instagram</a></li><li><a href="https://www.linkedin.com/company/national-institute-for-health-and-clinical-excellence">LinkedIn</a></li></ul></div></div><div class="Legal-module--wrapper--3AYMO"><div class="Legal-module--container--3TTBh"><nav class="Legal-module--menu--1e1Iy" aria-label="Legal menu"><ul><li><a href="https://www.nice.org.uk/accessibility">Accessibility</a></li><li><a href="https://www.nice.org.uk/freedom-of-information">Freedom of information</a></li><li><a href="https://www.nice.org.uk/glossary">Glossary</a></li><li><a href="https://www.nice.org.uk/terms-and-conditions">Terms and conditions</a></li><li><a href="https://www.nice.org.uk/privacy-notice">Privacy notice</a></li><li><a href="https://www.nice.org.uk/cookies">Cookies</a></li></ul></nav><p class="Legal-module--copyright--34nsI">©<!-- --> <abbr title="National Institute for Health and Care Excellence">NICE</abbr> <!-- -->2021<!-- -->. All rights reserved. Subject to<!-- --> <a href="https://www.nice.org.uk/terms-and-conditions#notice-of-rights">Notice of rights</a>.</p></div></div></footer></div><div id="gatsby-announcer" style="position:absolute;top:0;width:1px;height:1px;padding:0;overflow:hidden;clip:rect(0, 0, 0, 0);white-space:nowrap;border:0" aria-live="assertive" aria-atomic="true"></div></div><script id="gatsby-script-loader">/*<![CDATA[*/window.pagePath="/topics/nsaids-prescribing-issues/management/nsaids-prescribing-issues/";/*]]>*/</script><script id="gatsby-chunk-mapping">/*<![CDATA[*/window.___chunkMapping={"polyfill":["/polyfill-2cb897c2a056d28c9332.js"],"app":["/app-53a71c38b210970893c4.js"],"component---cache-caches-gatsby-plugin-offline-app-shell-js":["/component---cache-caches-gatsby-plugin-offline-app-shell-js-258fa972005c75a2a109.js"],"component---src-pages-404-tsx":["/component---src-pages-404-tsx.4b20f8dadfa146d0f95d.css","/component---src-pages-404-tsx-db046304e34e9a4e982b.js"],"component---src-pages-about-development-tsx":["/component---src-pages-about-development-tsx.4c5b5dd941fb0f6fd929.css","/component---src-pages-about-development-tsx-a805dcaba6372bd3fd34.js"],"component---src-pages-about-index-tsx":["/component---src-pages-about-index-tsx.a9a4b7f951b698486005.css","/component---src-pages-about-index-tsx-d5e998d3f688352286e1.js"],"component---src-pages-index-tsx":["/component---src-pages-index-tsx.49dafffcf9ae0c5f0d9f.css","/component---src-pages-index-tsx-6cc2ff789de11ec327f6.js"],"component---src-pages-search-tsx":["/component---src-pages-search-tsx.f915457cd8b05c27e895.css","/component---src-pages-search-tsx-a51f99760cb0d47808e2.js"],"component---src-pages-specialities-tsx":["/component---src-pages-specialities-tsx.fc62cf637c7ba1e609e7.css","/component---src-pages-specialities-tsx-90b8d3e5a5a3bff52a17.js"],"component---src-pages-topics-tsx":["/component---src-pages-topics-tsx.dfa0c1027e3cbeb11bdc.css","/component---src-pages-topics-tsx-960f75c13acbee11c017.js"],"component---src-pages-whats-new-tsx":["/component---src-pages-whats-new-tsx.7f7660f22ce5e07ac85a.css","/component---src-pages-whats-new-tsx-f78b713a66b42005fd9f.js"],"component---src-templates-chapter-level-1-chapter-level-1-tsx":["/component---src-templates-chapter-level-1-chapter-level-1-tsx.1a16ce552cccd7e50c41.css","/component---src-templates-chapter-level-1-chapter-level-1-tsx-0a03778bb80ba711929e.js"],"component---src-templates-chapter-level-2-chapter-level-2-tsx":["/component---src-templates-chapter-level-2-chapter-level-2-tsx.d09ef71dfbb262c31a03.css","/component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js"],"component---src-templates-speciality-speciality-tsx":["/component---src-templates-speciality-speciality-tsx.fc62cf637c7ba1e609e7.css","/component---src-templates-speciality-speciality-tsx-3357943d471e489a1b5f.js"],"component---src-templates-topic-topic-tsx":["/component---src-templates-topic-topic-tsx.afc04214919e241c3c2e.css","/component---src-templates-topic-topic-tsx-f17fe03d0b9a54a96aea.js"]};/*]]>*/</script><script src="../../../../polyfill-2cb897c2a056d28c9332.js" nomodule=""></script><script src="../../../../component---src-templates-chapter-level-2-chapter-level-2-tsx-3330d13663fb7ba90e1c.js" async=""></script><script src="../../../../0ad1f03a47300760909b2ab244b34289611800a7-fa70b32ffeeba2673019.js" async=""></script><script src="../../../../b95b9d9ffa67e6928854e772968693a58a7317d7-a9e1e5c953d4eee49b87.js" async=""></script><script src="../../../../app-53a71c38b210970893c4.js" async=""></script><script src="../../../../framework-34da02e39e1f104d9937.js" async=""></script><script src="../../../../webpack-runtime-28c424ef71f39faedaf0.js" async=""></script></body></html>